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CHAPTER I 
 
 
INTRODUCTION 
 
Glycosylation is the most common post-translational protein modification, involving the 
addition of chained sugars to modulate folding, localization and protein-protein interactions. 
Glycosylated proteins are most heavily concentrated on the extracellular side of the cell 
membrane, and most secreted proteins are glycosylated. Both of these glycoprotein classes are 
critical for cell-cell interactions, particularly during development. The nervous system appears 
selectively enriched for glycans and neurons appear particularly dependent on glycosylation in 
the regulation of synapse morphology and function. This thesis work probes the intersection 
between protein glycosylation and synaptic neuroscience, focusing on how loss of glycosylation 
results in neurological disease states.  
 
Synaptic Glycosylation 
The chemical synapse synaptomatrix 
A chemical synapse involves 1) a presynaptic signaling cell, 2) a postsynaptic receptive 
cell and 3) the extracellular space between (the synaptic cleft). The presynaptic axon terminates 
in swollen varicosities (synaptic boutons) that store the necessary machinery for transmission 
(Slater, 2015). A bouton can contain one to several specialized fusion sites (active zones) that 
contain the machinery for synaptic vesicles (SV) exocytosis. SVs are both localized in close 
proximity to each active zone (readily-releasable pool) and at a distance from the plasma 
membrane in a larger internal collection (reserve pool). SV fusion with the membrane releases 
neurotransmitter into the synaptic cleft, which is a highly organized, heavily-glycosylated 
cellular interface microenvironment (the synaptomatrix; Scott and Panin, 2014a,b). 
Glycosylated scaffolding proteins, signaling ligands, receptors, proteinases and many other 
glycans occupy this extracellular space and modulate the neurotransmission traveling to the 
postsynaptic cell. Unlike the general space between two cells, the synaptomatrix membranes 
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are held in rigid, close proximity, both restricting the extracellular proteins capable of occupying 
this space and also limiting the space that the neurotransmitter must travel (Rohrbough et al., 
2007). The neurotransmitter passes through the synaptomatrix to bind its appropriate receptor 
and elicit the postsynaptic response. Neurotransmitter ligand-gated ion channels allow passage 
of specific ions to change the voltage of the postsynaptic cell. The complex nature of synaptic 
communication as well as the multitude of components involved, reveal the myriad levels at 
which aberrant synaptic development and function can lead to neurological disease states.  
 
The Drosophila neuromuscular junction synapse model 
The neuromuscular junction (NMJ) is a specialized synapse formed by the connection of a 
presynaptic motoneuron on a postsynaptic muscle (Deshpande and Rodal, 2015; Menon et al., 
2013). The motoneuron axon terminates on the muscle surface and forms NMJ boutons, which 
are engulfed throughout development by folds of muscle membrane, the subsynaptic reticulum 
(SSR; Slater, 2015). The SSR is important for amplifying the synaptic signal throughout the 
muscle. SSR structural integrity is dependent on scaffolding molecules that aid in forming and 
holding the membrane in place. Mammalian extracellular components within the SSR 
membrane and synaptomatrix include neurotransmitter receptors, agrin, Dystroglycan, laminin 
and matrix metalloproteinases; all components that direct function, stabilization and 
development of the NMJ (Bloch-Gallego, 2015; Muntoni et al., 2008; Sanes and Lichtman, 
1999). The vertebrate NMJ is cholinergic with presynaptic release of acetylcholine 
neurotransmitter directed to postsynaptic acetylcholine receptors. Neurotransmitter passage 
thought the synaptic cleft is dependent on cell adhesion molecules that hold the pre and 
postsynaptic membrane in close proximity and maintain the stabilization of active zone 
components. Dystroglycan structurally connects intracellular cytoskeleton with extracellular 
laminin to support muscle strength and acetylcholine receptor clustering at the synapse. 
Presynaptically released agrin binds laminin and dystoglycan to direct and maintain 
acetylcholine receptors clustering (Bloch-Gallego, 2015). Matrix metalloproteinases cleave agrin 
to regulate its ability to bind laminin resulting in loss of the agrin-laminin complex and resultant 
acetylcholine receptor clustering (Patel et al., 2012).  Laminin also stabilizes presynaptic calcium  
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Figure 1  
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Figure 1: Ultrastructure of Drosophila Neuromuscular Junction 
The neuromuscular junction is composed of the presynaptic bouton, postsynaptic muscle and 
the extracellular synaptomatrix between both cells. The nerve’s axon terminates on the muscle 
in the form of boutons. The bouton stores all the necessary components for presynaptic release 
of neurotransmitter which is stored in hundreds of synaptic vesicles that appear like small 
circles with ultrastructural imaging. Along the edge of the bouton, dark regions can be seen 
where an increased number of synaptic vesicles congregate around machinery that facilitates 
synaptic vesicle fusion with the membrane, this is the location of the synapse. Several layers of 
membrane folds surround the bouton forming the subsynaptic reticulum (SSR), this region is 
important for amplifying the signal throughout the muscle.  
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channel clustering surrounding active zones which in turn recruit other presynaptic elements 
(Bloch-Gallego, 2015; Wu et al., 2010). These proteins are required to form a functionally active 
synapse, but likewise require glycan modification to carry out their function. After a synapse is 
formed it must be actively maintained or it will be degraded, active maintenance requires 
continued protein recruitment that is initiated through bidirectional trans-synaptic signals that 
drive synaptic protein translation.    
Studies using the Drosophila NMJ have greatly influenced our understanding of synaptic 
structural and functional development. Neuroligins, members of the cell adhesion molecules 
family, bind to neurexins forming a trans-synaptic connection between the pre and 
postsynaptic membrane (Chen et al., 2012; Xing et al., 2014). Loss of the neuroligin-neurexin 
complex results in aberrant bouton formation and synaptic transmission strength likely in part 
to disorganization of the SSR (Chen et al., 2012). The SSR is largely dependent on intracellular 
scaffolds to maintain the number and density of membrane folds. Loss of one particular 
scaffold, Discs Large (DLG), reduces the number and size of membrane folds in the SSR as well 
as reducing synaptic function (Blunk et al., 2014; Budnik et al., 1996; Lahey et al., 1994). 
Ultrastructural analysis of boutons reveals a similar synaptic structure seen in mammalian 
boutons with SSR surrounding a bouton that contains synaptic vesicles and active zones (Fig. 1). 
However, in Drosophila active zones are decorated by “T-bars” that serve to facilitate synaptic 
vesicle membrane fusion. Also in contrast to mammals, the Drosophila NMJ synapse is 
glutamatergic. The ease of physical access to Drosophila’s NMJ makes it a powerful synapse to 
study structural development and function. The larval body wall is lined with 30 muscles per 
hemisegment stereotypically arranged making identification of each muscle simple for 
experiment standardization (Fig. 2; Brent et al., 2009). Corresponding motoneurons within the 
neuropil project their axon through the cytoplasm to each target muscle. A simple dissection 
exposes the innervating axons and musculature allowing functional and structural assays.  
Synaptic transmission is assayed by clamping the muscle’s voltage, stimulating the axon and 
recording the resultant current that enters the muscle (Parkinson et al., 2013). Structural 
parameters are imaged and quantified to assay bouton number, branch number and overall  
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Figure 2 
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Figure 2: The Drosophila 3rd instar larval musculature 
The larval body wall is beautifully lined with a repeated muscle pattern containing 30 muscles in 
each segment. This pattern allows quick identification of each muscle providing a system to 
identify and study precise muscles and neuromuscular junctions for repeatability of 
experiments. The image was produced by cutting the dorsal side of the larval, removing all 
organs, pinning sides down, fixing and labeling all muscle tissue.  
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NMJ area. In addition to structure, protein scaffolds, active zones, trans-synaptic signals and 
glycans are easily labeled with antibodies and lectins at the NMJ to visualize quantity and 
localization. 
Drosophila trans-synaptic signaling  
Synaptogenic recruitment of presynaptic and extracellular scaffolds as well as active 
zone components requires bidirectional trans-synaptic signaling between the muscle and 
neuron in order to assure synaptic specificity and transmission integrity (Dani and Broadie, 
2012). During larval development the muscle grows 100 fold which requires corresponding NMJ 
development to maintain stimulation strength. If the NMJ does not expand with muscle growth, 
neural stimulation will become weak and unable to elicit a muscle contraction. However 
conversely, if neural stimulation is too great then the muscle will be unable to repolarize in a 
timely manner, this is particularly important for fast acting muscles. Thus, throughout muscle 
development neural size needs to correspond to maintain proper muscle stimulation. To 
maintain synaptic transmission that is “just right”, the neuron and muscle constantly send 
trans-synaptic signals back and forth in order to increase or decrease synaptic strength, fine-
tuning the developing synapse. Trans-synaptic signals drive the translation and recruitment of 
synaptic building blocks for transmission, but also cell adhesion molecules such as neurexin, 
neuroligin and fasciclin 2 that are required to maintain synapse integrity. Neurexin forms a 
complex with neuroligin to modulate synapse development. Loss of Drosophila neuroligin 2 
causes a reduction of bouton number, aberrant SSR development and impaired synaptic 
transmission (Chen et al., 2012). Fasciclin 2 is expressed both pre and postsynaptically and 
forms a homodimer across the synapse (Schuster et al., 1996; Spring et al., 2016). This trans-
synaptic complex is not required to form the synapse but is required to maintain the synaptic 
connection, loss of Fas2 either pre or postsynaptically drives bouton retraction. These cell 
adhesion molecules communicate through direct physical trans-synaptic interactions.  In 
addition to physical complex formation, the NMJ communicates through trans-synaptic signals 
that drive the recruitment of these synaptic proteins required to expand and maintain the 
developing NMJ.  
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Three particularly well-characterized trans-synaptic signals at the Drosophila NMJ are 
Wnt Wingless (Wg), BMP Glass Bottom Boat (Gbb), and Jelly Belly (Jeb) (Grosso et al., 2011; 
Kamimura et al., 2013; Rohrbough and Broadie, 2010; Tanaka et al., 2002). The Wnt signal, Wg, 
drives the development of pre and postsynapse active zones, boutons and SSR formation 
(Mosca and Schwarz, 2010). Wg is secreted presynaptically and binds postsynaptic Frizzled 2 
receptors that are then internalized, cleaved and transported to the nucleus to initiate synaptic 
protein translation (Ataman et al., 2008; Korkut and Budnik, 2009). The integrity of Wg signaling 
on Frz2 receptors requires the co-receptor Dally-like-protein (Dlp), a GPI anchored glycoprotein 
that is proposed to temporarily bind Wg causing its accumulation near Frz2 receptors (Dear et 
al., 2016; Yan et al., 2009). The BMP signal, Gbb, is postsynaptically released and binds its 
presynaptic receptors that include wishful thinking (Wit), thick veins (Tkv) and saxophone (Sax) 
to drive transcription of neural proteins (Haghighi et al., 2003; Kim and Marques, 2010; McCabe 
et al., 2003; Nahm et al., 2010). Loss of Gbb signaling at the NMJs causes reduced boutons, 
active zone t-bars and synaptic transmission. Jeb is released presynaptically and binds 
postsynaptic anaplastic lymphoma kinase (Alk) receptors (Rohrbough et al., 2013). Activation of 
the Alk receptor reduces the muscles response to neural transmission, revealing a trans-
synaptic pathway that negatively regulates synaptic activity. Loss and overexpression of these 
trans-synaptic signals and cell adhesion molecules alter the development of the NMJ synapse 
causing altered synaptic function and structure (Dani and Broadie, 2012). Synaptogenic events 
are regulated by bidirectional trans-synaptic signals that traverse the synaptomatrix, and 
glycosylation of both ligands and receptors alters localization and binding (Henriquez and 
Salinas, 2012; Patton, 2003). 
Drosophila NMJ synaptic glycosylation  
Most cells are coated with a glycocalyx (Abu-Qarn et al., 2008), with carbohydrate 
chains on proteins and lipids heavily decorating the plasma membrane’s outter leaflet. At the 
synapse, the heavily-glycosylated synaptomatrix is composed of secreted and membrane-
bound molecules residing at the interface between presynaptic active zone and postsynaptic 
receptor field. In Drosophila, genetic analyses show synaptomatrix glycan modification/binding 
has core roles in both structural and functional NMJ development (Broadie et al., 2011; Dani 
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and Broadie, 2012). Known glycan-dependent synaptogenic events include presynaptic active 
zone (AZ) differentiation, postsynaptic glutamate receptor (GluR) localization and ECM 
organization within the synaptic cleft, driven by the secreted endogenous lectin Mind-the-Gap 
(MTG) (Dani et al., 2012; Long et al., 2008; Rushton et al., 2012). The majority of extracellular 
synaptic proteins are glycosylated, which can be visualized by lectins that bind specific glycan 
branches or chains (Jumbo-Lucioni et al., 2014).  For example, Vicia villosa (VVA) labels n-
acetylgalactosamine glycans; antibody against Horse Radish Peroxidase (HRP) labels 
bifucosylated N-glycans; Erythrina cristagalli (ECL) binds to D-galactose glycans; all are 
particularly highly enriched at the Drosophila NMJ (Parkinson et al., 2013). Several other lectins 
have been used to visualize glycan composition revealing a heavy contribution of glycosylation 
at the NMJ (Dani et al., 2014; Jumbo-Lucioni et al., 2014). Lectins bind specific glycans but are 
not specific for proteins, so loss of lectin labeling does not necessarily mean loss of proteins. An 
antibody against Horse Radish Peroxidase (HRP) labels N-glycans that are bi-fucosylated, and 
this label has been classically used to visualize the Drosophila NMJ. The extensive lectin binding 
at the NMJ highlights the multitude of glycoproteins that both form the synapse and regulate 
its activity.   
The majority of extracellular proteins at the synapse are glycosylation (Schachter and 
Boulianne, 2011; Scott and Panin, 2014). Proteins are glycosylated with a highly varied level of 
necessity, some proteins require glycosylation to fold properly or function whereas others 
seemingly receive glycan modifications without purpose or benefit. At the Drosophila NMJ 
there are several examples of glycoproteins that require their glycan modification for structural 
and functional integrity of the synapse while the role for other N-glycan modifications has not 
been identified. The Wg trans-synaptic pathway is a good example of N-glycosylation 
modification. Wg signaling molecule itself is N-glycosylated but its removal has not shown any 
effects on signal transmission to the muscle. The co-receptor DLP is highly glycosylated and it is 
these glycan chains that enhance its binding to Wg (Yan et al., 2009). Additionally, DLP is GPI 
anchored which requires three mannose residues that have been modified by glycosylation 
enzymes. Dystroglycan is heavily glycosylated in vertebrates and loss of these glycan 
modifications cause congenital muscular dystrophies. Likewise, Drosophila Dystroglycan is 
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glycosylated and its loss causes a reduction in Dystroglycan at the NMJ, reduced quantal 
content (strength of neurotransmitter in an individual SV) and postsynaptic glutamate receptor 
composition (Wairkar et al., 2008). Loss of glycosylation on specific glycoproteins often leads to 
loss of protein function as seen above, but with loss of the enzymes responsible for 
glycosylation the impact is more widespread impacting proteins in several pathways.  
 
N-Linked Glycosylation 
N-Linked Glycosylation Pathway  
The major focus of this thesis is the intersection of N-linked glycosylation and NMJ 
synaptic development. Most extracellular secreted and transmembrane proteins are N-
glycosylated in the ER (Schachter and Boulianne, 2011; Scott and Panin, 2014). The addition 
occurs on one or more asparagines per protein within the three amino acid consensus 
sequence (asparagine-X-serine/threonine), with X being any amino acid other than proline. All 
N-linked glycans begin with the same 14-oligosaccharide transferred from a modified lipid 
(dolichol) by the oligosaccharide transferase complex (OST, Fig. 3). The process begins in the 
cytosol with the addition of N-acetyl-glucosamine (GlcNac) to dolichol phosphate, followed by 
the addition of a second GlcNac and then 5 mannose sugars. This 7-oligosaccharide is then 
flipped into the ER lumen by RFT1 flippase (Ondruskova et al., 2012), after which 4 mannose 
and 3 glucose sugars are added in sequential order. The 14-oligosaccharide is then transferred 
by the OST onto the asparagine in the co-translational protein transport mechanism (Fig. 3). 
Soon after addition, the oligossacharide is trimmed by glycanases to a 12-oligosaccharide 
recognized by chaperone proteins (calnexin and calreticulin) that aid folding (Lannoo and 
Damme, 2015; Wang et al., 2015). Improper folding results in trimming to a 9-oligosaccharide 
structure, which targets the protein for ERAD pathway degradation (Julio and Parodi, 2015; 
Lannoo and Damme, 2015). A properly folded protein is sent along the ER to Golgi pathway as 
the glycan is further trimmed to a 7-oligosaccharide and an N-acetyl-glucosamine is added by 
mgat1 (Fig. 3). From this step foward, the N-glycosylation pathway differs between organisms, 
but involves the addition and cleavage of more sugars to generate a myriad of differentially  
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Figure 3  
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Figure 3: Drosophila N-Linked Glycosylation Pathway with CDGs 
A) GDP-Mannose and Dolichol-Mannose are derived from glucose and required for the 
assembly of the N-glycan oligosaccharide. Each step of glucose’s conversion requires enzymatic 
activity that if mutated results in a Congenital Disorder of Glycosylation. GDP-mannose is 
required building the oligosaccharide in the cytosol and dolichol-mannose is required for 
addition of mannose in the ER and Golgi lumen. B) Building the N-glycan oligosaccharide is a 
linear process up to the addition of GlcNAc by Mgat1 and highly conserved in Drosophila. Post 
Mgat1’s function the pathway of glycan modification splits into several directions and can be 
modified by different glycans and branching patterns. Glycan patterns that require Mgat1 
function are depicted in the outlined section labeled “Required Mgat1 Function” and are absent 
in the mgat1 mutant. Congenital Disorders of Glycosylation (CDG) result from mutation of 
glycosylation enzymes that reduce enzymatic activity and are shown.  
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glycosylated structures. For further details regarding the glycosylation pathway please see 
Essentials of Glycobiology (Varki et al., 2009). 
N-linked glycosylation at the synapse  
Hundreds of synaptic proteins are glycosylated, spanning multiple aspects of synapse 
structure and function development, as well as transmission modulation (Koles et al., 2007). On 
the presynaptic side, glycan dependent proteins includes synaptic vesicle protein 2 (SV2) and 
synaptophysin (Kwon and Chapman, 2012). SV2 has three N-glycan binding sites that are 
required for transport of SV2 to synaptic vesicles and its role in synaptic vesicle priming and 
recycling. Synaptophysin has only one N-glycan attachment but it is required for trafficking to 
synaptic vesicles and its loss results in reduced recycling. Within the synaptic cleft, extracellular 
glycoproteins include Dystroglycan, agrin and laminin (Broadie et al., 2011; Martin, 2003). Loss 
of these extracellular glycoproteins or their glycosylation can results in weakened membrane 
integrity and cell-cell connectivity. The glycans that modify Dystroglycan bind to laminin, loss of 
these glycans results in severe muscular dystrophies characterized by muscle weakness. Loss of 
the enzyme O-fucosyltransferase I that adds fucose to agrin results in an increase in 
acetylcholine receptors caused by the loss of agrin glycosylation; revealing a negative 
regulatory mechanism for glycosylation (Kim et al., 2008). On the postsynaptic side both 
acetylcholine and glutamate receptors are glycosylated. Acetylcholine receptor glycosylation 
regulates channel gating, whereas the glutamate receptors require glycosylation for trafficking 
to the synaptic membrane (Engel et al., 2015; Scott and Panin, 2014). Reduced glycosylation on 
acetylcholine receptors causes loss of synaptic transmission and results in congenital 
myasthenia syndrome in humans. See the following reviews on N-glycosylation of the nervous 
system (Dani et al., 2012; Scott and Panin, 2014 a, b).  
 
Congenital Disorders of Glycosylation 
Clinical diagnosis and symptoms 
Congenital Disorders of Glycosylation (CDGs) occur when the glycosylation pathway is 
impaired via mutations reducing enzymatic activity (Scott et al 2014). Table 1 outlines the 
known N-linked CDGs, and Figure 3 depicts the enzyme location of CDGs within the N-linked 
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glycosylation pathway. CDGs typically manifest in hypomorphic heteroallelic conditions (two 
different partial loss of function mutations), in which patients maintain partial function of the 
mutated enzyme allowing some glycosylation to continue through the bottleneck but still 
hampers further glycan modifications resulting in disease conditions based on the amount of 
remaining enzymatic activity. Although CDGs are individually rare disease states, more CDG 
patients are being revealed due to advances in medical technology and a greater understanding 
of glycan related disorders (Hennet, 2012). Previously unidentified diseases are being defined 
as CDGs, with many more predicted but still unidentified due to a lack of routine testing. 
Altered blood serum glycosylation levels point to a potential CDG, and direct sequencing is 
required to identify the specific CDG, which is very important for treatment. CDG patients 
present with multi-system symptoms ranging from neurological, liver, intestinal and hepatic 
(Paragon et al., 2014), with blood defects, metabolic impairments, hypothyroidism and 
disorders with facial cranial development, skin, hypotonia, immune systems and general failure 
to thrive. In many cases, there are striking neurological problems (Paragon et al., 2014). The 
nervous system is particularly affected by glycan loss, as is evident by the high percentage of 
CDG patients presenting with neurological impairment.  
Greater than 80% of CDGs cause a neurological deficiency, which can affect both the 
central and peripheral nervous system (Barone et al., 2014). In the central nervous system, 
reduced cerebral development, microcephaly, epilepsy, ataxia and mental retardation are all 
common in CDG patients. The peripheral nervous system can present with motor ataxia, muscle 
weakness and reduced limb control with a wide range of severity. Some CDGs primarily cause 
peripheral impairment, such as movement control at the neuromuscular junction, while others 
cause severe selective brain impairment, such as intellectual disability. The most common CDG 
(PMM2-CDG, >1000 patients) presents with neurological impairments including cerebellar 
atrophy causing ataxia and locomotion deficiencies, forcing many PMM2-CDG patients to be 
wheelchair-bound (Barone et al., 2014). Many CDG patients have intellectual disability caused 
by CNS involvement but some are mentally fully capable with only slight ataxia. The wide range 
of disease presentation is caused in part by the hypomorphic nature of most CDG disease 
states, with partial function of the causative enzyme allowing some level of glycosylation but  
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CDG Name Enzyme Name/ function Gene 
Symbol 
CG 
number 
  Glycan Precursors     
PGM1-CDG phosphoglucomutase activity PGM1 5165 
  phosphoglucoisomerase  PGI 8251 
MPI-CDG phosphomannose isomerase  MPI 8417 
PMM2-CDG phosphomannomutase 2 PMM2 10688 
GMPPA-CDG mannose-1-phosphate guanylyltransferase 
activity 
GMPPA 8207 
GMPPB-CDG GDP-mannose pyrophosphorylase B GMPPB 1129 
MPDU1-CDG Mannose-P-dolichol utilization defect 1 
protein 
MPDU1 3792 
Dolk-CDG dolichol phosphokinase  Dolk 8311 
        
  Sugar Transporters     
SLC35C1-CDG GDP-fucose transmembrane transporter 
activity 
SLC35C1 9620 
SLC35CA2-
CDG 
UDP-galactose transmembrane transporter 
activity 
SLC35A2 2675 
        
  ER Oligosaccharide Building     
DPAGT1-CDG UDP-N-acetylglucosamine—dolichyl-
phosphate N-
acetylglucosaminephosphotransferase 
DPAGT1  or  
Alg7 
5287 
ALG13-CDG  UDP-N-acetylglucosaminyltransferase subunit ALG13 14512 
ALG14-CDG N-acetylglucosaminyldiphosphodolichol N-
acetylglucosaminyltransferase anchoring 
subunit 
ALG14 6308 
ALG1-CDG Chitobiosyldiphosphodolichol beta-
mannosyltransferase 
ALG1 18012 
ALG2-CDG Alpha-1,3-mannosyltransferase ALG2 1291 
ALG11-CDG Asparagine-linked glycosylation protein 11 ALG11 11306 
RFT1-CDG Man5GlcNAc2-PP-Dol flippase  RFT1 3149 
ALG3-CDG Dolichyl-P-Man:Man(5)GlcNAc(2)-PP-dolichyl 
mannosyltransferase 
ALG3 4084 
ALG12-CDG Dolichyl-P-Man:Man(7)GlcNAc(2)-PP-dolichyl-
alpha-1,6-mannosyltransferase 
ALG12 8412 
ALG9-CDG Alpha-1,2-mannosyltransferase  ALG9 11851 
ALG6-CDG Dolichyl pyrophosphate Man9GlcNAc2 alpha-
1,3-glucosyltransferase 
ALG6 5091 
ALG8-CDG dolichyl pyrophosphate Glc1Man9GlcNAc2 
alpha-1,3-glucosyltransferase 
ALG8 4542 
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  Alpha 3-glucosyltransferase ALG10 32076 
DPM1-CDG Dolichol-phosphate mannosyltransferase Dpm1 10166 
DPM3-CDG Dolichol-phosphate mannosyltransferase 
subunit 3 
DPM3 33977 
DPM2-CDG Dolichol phosphate-mannose biosynthesis 
regulatory 
DPM2 42456 
        
 Oligosaccharide Complex     
TUSC3-CDG Oligosaccharyl transferase complex, subunit 
OST3/OST6 
  7830 
  Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit Swp1 
  6370 
STT3A-CDG Oligosaccharyl transferase, STT3 subunit   7748 
STT3B-CDG Oligosaccharyl transferase, STT3 subunit   1518 
SSR4-CDG Translocon-associated protein δ    or    Signal 
Sequence Receptor 4 (SSR4) 
  9035 
DDOST-CDG Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase 48 kDa subunit 
  9022 
  dolichyl-diphosphooligosaccharide-protein 
glycotransferase activity 
  13393 
        
 Glycan Cleaving Enzymes     
MOGS-CDG 
OR GCS1-CDG 
Mannosyl-oligosaccharide glucosidase MOGS   or  
GCS1 
1597 
  alpha-1,4-glucosidase activity ganab 14476 
  mannosyl-oligosaccharide 1,2-alpha-
mannosidase activity 
  32684 
MAN1B1-CDG Endoplasmic reticulum mannosyl-
oligosaccharide 1,2-alpha-mannosidase 
MAN1B1 11874 
  mannosyl-oligosaccharide 1,2-alpha-
mannosidase activity 
alpha-Man-
1c 
31202 
        
 Golgi Glycan Modifications     
  mannosyl (alpha-1,3-)-glycoprotein beta-1,2-
N-acetylglucosaminyltransferase 
mgat1 13431 
  mannosyl-oligosaccharide 1,3-1,6-alpha-
mannosidase activity 
α 
Mannosidase 
II a 
18802 
  mannosyl-oligosaccharide 1,3-1,6-alpha-
mannosidase activity 
α-Man-IIb 4606 
Mgat2-CDG Alpha-1,6-mannosyl-glycoprotein 2-beta-N-
acetylglucosaminyltransferase 
mgat2 7921 
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  alpha(1,6)-fucosyltransferase FucT6 2448 
  beta-N-acetylglucosaminidase activity   8824 
 alpha(1,3)-fucosyltransferase    6869 
 alpha-(1->3)-fucosyltransferase activity   4435 
  UDP-glucose:Glycoprotein 
Glucosyltransferase 
  6850 
  dolichyl-phosphate beta-glucosyltransferase 
activity 
  7870 
 
 
Table 1: Congenital Disorders of Glycosylation with Drosophila homologs 
N-Linked Congenital Disorders of Glysolation (CDG) are listed in column 1 with N-glycosylation 
pathway enzymes in column 2. Commonly used abbreviations are listed in column 3 and all 
known Drosophila homologs are shown in column 4. This table will need to be exapanded as 
new enzymes, genes and CDGs are identified.  
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not full activity. This disease range is further broadened by unknown factors. Siblings with 
identical mutants have been shown to present very differently due to unknown genetic 
background and/or environmental factors. Given our current level of understanding, CDG 
treatment strategies are primarily limited to alleviating symptoms.        
To date there are only three somewhat treatable CDGs: DPAGT1-CDG, MPI-CDG and 
PGMI-CDG. DPAGT1-CDG blocks the first step in building the dolichol-oligosaccharide, and 
results in a congenital myasthenic syndrome (CMS), a condition with muscle weakness caused 
by loss of glycosylation of NMJ acetylcholine receptors (Scott et al., 2014). Cholinesterase 
inhibitors increase available neurotransmitter to activate the reduced acetylcholine receptor 
number and restore some muscle strength, but most DPAGT1-CDG patients die before 1 year 
old due to additional disabilities (Belaya et al., 2012). MPI-CDG patients have severe 
multisystem impairment caused by a reduction in available mannose-6-phosphate, a glycan 
precursor required to build the N-oligosaccharide. High doses of mannose and heparin 
treatments can restore mannose levels, however developmental abnormalities that occur prior 
to mannose supplementation can still be severe and can require organ transplantation (Pagon 
et al., 2014; Scott et al., 2014). PGMI-CDG patients present with reduced galactosylation 
resulting in multisystem impairments caused by defects in the bidirectional interconversion of 
glucose-1-phosphate and glucose-6-phosphate. Galactose supplements improve liver function, 
hypoglycemia and abnormal coagulation (Scott et al., 2014; Tegtmeyer et al., 2014). Overall, 
CDG treatments are very limited and in no case completely correct disease states. The greatest 
barrier to developing treatments is the lack of understanding of the disease conditions on a 
cellular and molecular level. Future studies using animal models are required to gain a better 
understanding of the affected glycoprotein pathways, especially for neurological symptoms. 
 
Synaptic CDG disease models 
Synaptic defects are the leading hypothesized cause for neurological CDG disease states.  
For example, loss of dystroglycan glycosylation results in dystroglycanopathies, a form of 
muscular dystrophy caused by the inability of dystroglycan to bind its extracellular partners: 
laminin, neurexin and agrin (Kirschner, 2013). Muscular dystrophies present with severe muscle 
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failure and associated movement impairments, with intracellular NMJ components (dystrophin) 
unable to bind extracellular partners resulting in muscle weakness and failure to illicit strong 
movement. Mammailian models reveal strong requirement for glycosylation on a protein to 
protein basis, but models for CDGs that impact potentially dozens or hundreds of proteins are 
limited. Mouse CDG models have been somewhat useful for understanding glycosylation 
defects in multiple organ systems but have only been generated for 9 CDG conditions: PMI-
CDG, PMM2-CDG, SRD5A3-CDG, DPAGT1-CDG, MGAT2-CDG, SLC35C1-CDG, B4GALT1-CDG, 
GNE-CDG and GALNT3-CDG (Schwarzkopf et al., 2002; Thiel and Korner, 2010; Yoshida et al., 
2014). However, of these nine mouse models, none have resulted in synaptic characterization 
of any neural implications (Asano et al., 1997; Cantagrel et al., 2010; Malicdan et al., 2009; 
Malicdan et al., 2007; Hellbusch et al., 2007; Lu et al., 1997; Marek et al., 1999; Schneider et al., 
2011; Schwarzkopf et al., 2002; Sharma et al., 2014; Ye and Marth, 2004; Yoshida et al., 2014).  
The lack of synaptic characterization in many of these models is causes by early lethality in null 
mutants or the lack of phenotypes with hypomorphic conditions that do not reduce activity 
adequately. The need still remains to study loss of function mutants but in a model system that 
can tightly regulate the degree of reduction in order to produce a disease state but not 
embryonic lethality.  
Drosophila has been used extensively to model human disease states, but to date only a 
few CDG-causing genes have been extensively studied. Drosophila neurally altered 
carbohydrate gene (nac) encodes a Golgi fucose transporter required for the production of the 
HRP epitope, a bifucosylated N-glycan (Geisler et al., 2012; Katz et al., 1988; Whitlock, 1993). 
Loss of nac in wing neurons results in axonal misrouting. The role for the HRP epitope is largely 
unknown but expected to play a role in axonal projections. A transgenic RNAi screen of 
glycosylation related gene function at the Drosophila NMJ (Dani et al., 2012) uncovered a 
common role for glycosylation restricting both structure and function. Follow-up work on two 
hits from this screen, heparan sulfate proteoglycan (HSPG) sulfotransferase (hs6st) and 
sulfatase (sulf1), revealed a bidirectional disruption of both the WNT (Wingless, Wg) and BMP 
(Glass Bottom Boat, Gbb) trans-synaptic signaling pathways. Both hs6st and sulf1 mutants had 
overabundant NMJ structure whereas synaptic transmission strength was increased in the sulf1 
21 
 
mutant but decreased in the hs6st mutant. Subsequent studies on other screen hits, two N-
acetyl-galactosamine transferases (pgant), showed regulation of synaptic development via 
trans-synaptic integrin signaling (Dani et al., 2014). Reduction of either pgant caused increased 
neural transmission and structural overelaboration at the NMJ. Pre and postsynaptic active 
zone components were more abundant and ultrastructural investigation revealed increased 
synaptic vesicle number around the presynaptic active zone T-bars. A specific CDG synaptic 
disease model that came out of this screen, Classic Galactosemia (Galt), identified aberrant 
components of Wingless trans-synaptic signaling (Jumbo-Lucioni et al., 2014). Similar to the 
general trend for glycosylation mutants, both NMJ structure and function were elevated in the 
Galt mutants. In addition to the above genes, several N-glycosylation CDG causing genes have 
yet to be studied further that were identified in the initial screen: Mgat2, PMM2, MOGS, 
MAN1B1, ALG10, ALG8, SLC35C1 and GMPPA. Each of these studies identified disruption of 
trans-synaptic signaling to be a common root causing compromised NMJ synaptogenesis 
underlying movement impairments. Ongoing Drosophila work aims at understanding these 
impairments in these disease states for the ultimate goal of improving CDG patient treatment 
and care.  
 
Thesis Outline 
MGAT1  
The focus of the first half of this thesis is on the role of the mgat1 gene encoding 
Mannosyl (α-1,3-)-glycoprotein β-1,2-N-acetylglucosaminyltransferase (GlcNAcT1). This 
enzymatic function is a prerequisite for producing all hybrid and complex N-glycosylation 
(Pownall et al., 1992; Ye and Marth, 2004), and without mgat1 function all hybrid and complex 
N-glycan production is restricted (Fig. 3) (Puthalakath et al., 1996; Schachter, 2010). 
Importantly, this represents the most severe truncation of the N-glycosylation pathway that 
permits Drosophila viability, and therefore allows study of the consequences at the NMJ 
synapse. Proteins are glycosylated in the mgat1 mutant and are decorated with high mannose 
structures, which permits protein folding, but provides a model to study the impact of hybrid 
and complex glycans on synapse development. Mgat1-dependent N-glycosylation modifies 
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many synaptic proteins including neurotransmitter receptors, Fasciclins, Neuroglians, Neurexins 
and Dystroglycans (Koles et al., 2007; Muntoni et al., 2008; Sun and Xie, 2012). Mouse mgat1 
knockouts are lethal at E9.5, but conditional mutants show movement defects, tremors, 
paralysis and early death characteristic of neurodevelopmental impairments (Campbell et al., 
1995; Grasa et al., 2012; Shi et al., 2004; Ye and Marth, 2004). Drosophila mgat1 mutants are 
adult viable, but have reduced lifespan due to a specific neural requirement (Sarkar et al., 2006; 
Sarkar et al., 2010; Schachter and Boulianne, 2011). Neurally reduced mgat1 reveals a striking 
locomotion deficiency and loss of the HRP glycan labeling that characterizes neuronal tissue 
(Desai et al., 1994; Paschinger et al., 2009; Sarkar et al., 2006). Interestingly, mgat1 
overexpression in neurons rescues the mgat1 null mutant and even extends lifespan, 
implicating a neuronal role for complex and hydrid glycosylation in increasing the conditioning 
of the animal, although through unknown mechanisms.  
Our work focused on characterizing hybrid and complex N-glycosylation roles at the 
Drosophila NMJ. We identify overabundant structural morphology and elevated synaptic 
transmission in the mgat1 mutants. Synaptic vesicle number within the bouton is increased and 
likely accounts in part for the elevated neurotransmission. Trans-synaptic signaling molecules 
that drive the recruitment of synaptic proteins are also altered with an increase in Wg but 
decrease in both Gbb and Jeb within the synapse. Likely results of aberrant trans-synaptic 
signaling, two intracellular scaffolds are reduced resulting in presynaptic SSR distribution and 
folding errors. We conclude that Mgat1-dependent N-glycosylation shapes the synaptomatrix 
glycan environment to facilitate transmission of trans-synaptic signaling ligands driving synaptic 
scaffold recruitment during synaptogenesis.  
 
PMM2  
The focus of the second half of this thesis is on the PMM2-CDG disease gene 
phosphomannomutase 2 (pmm2), the enzyme responsible for converting mannose-6-
phosphate into mannose-1-phosphate, an obligatory precursory required in building the N-
glycan oligosaccharide (Andreotti et al., 2014; Freeze et al., 2014; Freeze et al., 2015). PMM2 
functions very early in the N-glycosylation pathway prior to the building of the oligosaccharide 
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on dolichol so loss of pmm2 results in the complete loss of all N-glycosylation. Since the first 
patient in 1980, >100 different mutations in >1000 PMM2-CDG patients have been 
characterized (Freeze et al., 2014; Haeuptle and Hennet, 2009; Jaeken, 2013; Jaeken et al., 
1980; Yuste-Checa et al., 2015). PMM2-CDG infant mortality is ~20% in the first year, with 
patients manifesting subsequent increased susceptibility to organ failure, infection and injury 
(Grunewald, 2009). PMM2-CDG patients present with a spectrum of neurological symptoms 
(Jaeken, 2013), ranging from severe neurological impairments with early death, to mild defects 
with slight psychomotor delay (Grunewald, 2009; Marquardt and Denecke, 2003). The first 
PMM2-CDG mouse model showed early embryonic lethal, which limited its usefulness (Thiel et 
al., 2006). Heteroallelic combination of two PMM2 mutations allows partial enzymatic activity, 
protracted embryonic survival and has demonstrated potential maternal dietary intervention in 
treatment (Schneider et al., 2011).  In this study, feeding mannose to mothers during gestation 
further increased offspring lifespan. These results gave hope for PMM2-CDG patients, but 
mannose treatments for patients have showed no benefit (Kjaergaard et al., 1998; Mayatepek 
and Kohlmuller, 1998). However, patients with PMI-CDG (phosphomannoisomerase, converts 
fructose-6-phosphate into mannose-6-phosphate) respond favorably to mannose 
supplementation, and hepato-intenstinal conditions are strongly improved (Jenssen et al., 
2014). Recently, a PMI-CDG mouse model showed a detrimental response to mannose 
supplementation (Sharma et al., 2014). Hypomorphic PMI-CDG mice with PMI loss similar to 
human patients did not present with any noticeable disease conditions. However, mannose 
supplementation early in development resulted in eye defects revealing a potential disease 
causing role for increase mannsose-6-phosphate. A subsequent zebrafish model via PMM2 
morpholino knockdown revealed altered development, reduced motility and altered glycan 
profiles (Cline et al., 2012). Most recently, a similar Xenopus morpholino knockdown model 
demonstrated strong reduction in Wnt signaling, revealing a PMM2 requirement in intercellular 
communication (Himmelreich et al., 2015). For this thesis work, I produced and characterized 
Drosophila pmm2 mutants, showing the characteristic failure to thrive, loss of coordinated 
movement and reduced N-glycosylation, with severity corresponding to the degree of pmm2 
reduction.  We therefore set out to develop a Drosophila PMM2-CDG disease model.  
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  Here, we report the generation and characterization of the first Drosophila PMM2-CDG 
model. CRISPR-generated Drosophila pmm2 null mutants display severely disrupted 
glycosylation and early lethality. Partial loss of function mutants display incoordination and 
later lethality corresponding to the reduction of pmm2. Analyses of the well-characterized 
Drosophila neuromuscular junction (NMJ) reveal synaptic glycosylation loss accompanied by 
structural architecture and functional neurotransmission defects. Matrix metalloproteinase 2 
(MMP2) is identified as one of the extracellular enzymes with restricted glycosylation resulting 
in reduced expression of MMP2 at the NMJ. Wnt Wingless (Wg) trans-synaptic signaling is 
likewise affected with a loss of synaptic Wg ligand, its co-receptor Dlp and downstream 
transcriptional regulator Frizzled 2 at the muscle nuclei. Taken together, we propose a model 
for pmm2 dependent glycosylation of synaptic proteins, enzymes and trans-synaptic signaling 
that drive synaptic development and maturation. 
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Summary  
Neural development requires N-glycosylation regulation of intercellular signaling, but 
the requirements in synaptogenesis have not been well tested. All complex and hybrid N-
glycosylation requires Mgat1(UDP-GlcNAc:-3-D-mannoside-1,2-N-acetylglucosaminyl 
transferase I) function, and mgat1 nulls are the most compromised N-glycosylation condition 
that survive long enough to permit synaptogenesis studies. At the Drosophila neuromuscular 
junction (NMJ), mgat1 mutants display selective loss of lectin-defined carbohydrates in the 
extracellular synaptomatrix, and an accompanying accumulation of the secreted endogenous 
Mind-the-Gap (MTG) lectin, a key synaptogenesis regulator. Null mgat1 mutants exhibit 
strongly overelaborated synaptic structural development, consistent with inhibitory roles for 
complex/hybrid N-glycans in morphological synaptogenesis, and strengthened functional 
synapse differentiation, consistent with synaptogenic MTG functions. Synapse molecular 
composition is surprisingly selectively altered, with decreases in presynaptic active zone 
Bruchpilot (BRP) and postsynaptic glutamate receptor subtype B (GluRIIB), but no detectable 
change in a wide range of other synaptic components. Synaptogenesis is driven by bidirectional 
trans-synaptic signals that traverse the glycan-rich synaptomatrix, and mgat1 mutation disrupts 
both anterograde and retrograde signals, consistent with MTG regulation of trans-synaptic 
signaling. Downstream of intercellular signaling, pre- and postsynaptic scaffolds are recruited to 
drive synaptogenesis, and mgat1 mutants exhibit loss of both classic Discs Large (DLG) and 
newly-defined Lethal Giant Larvae (LGL) scaffolds. We conclude that Mgat1-dependent N-
glycosylation shapes the synaptomatrix carbohydrate environment and endogenous lectin 
localization within this domain, to modulate retention of trans-synaptic signaling ligands driving 
synaptic scaffold recruitment during synaptogenesis.  
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Introduction 
 N-glycosylation is the most common posttranslational modification, involving linkage of 
diverse carbohydrate trees onto asparagine, targeting primarily cell surface and secreted 
proteins. Mutation of >20 human N-glycosylation genes result in heritable congenital disorders 
of glycosylation (CDGs), many of which impair nervous system development (Freeze, 2006; 
Hennet, 2012; Hewitt, 2009). The mgat1 gene encoded GlcNAcT1 adds GlcNAc to high-mannose 
sites (Schachter, 2010); an essential early step in producing all complex and hybrid N-glycans 
(Pownall et al., 1992; Ye and Marth, 2004). Thus, Mgat1 generates the entire repertoire of 
polymeric branched N-glycans destined for secretion or presentation on the cell surface 
(Puthalakath et al., 1996); and mgat1 null mutants, containing high mannose in place of 
complex/hybrid N-glycans, are the earliest N-glycan pathway block available to study N-
glycosylation requirements in neural development (Schachter and Boulianne, 2011). Mouse 
mgat1 knockouts are lethal at E9.5, but conditional mutants show movement defects, tremors, 
paralysis and early death characteristic of neurodevelopmental impairments (Campbell et al., 
1995; Grasa et al., 2012; Shi et al., 2004; Ye and Marth, 2004). Drosophila mgat1 is functionally 
conserved, and null mutants show the same range of crippling neurological defects, but have 
the enormous benefit for analysis of being viable. 
 Drosophila mgat1 null mutants exhibit severely impaired coordinated movement, and 
the few adults that eclose usually survive only a few days (Sarkar et al., 2006). Importantly, 
lifespan shortening is due entirely to neuron-specific requirements, and mgat1 neuronal 
overexpression increases lifespan (Sarkar et al., 2010; Schachter and Boulianne, 2011). In the 
central brain Mushroom Body learning/memory center, mgat1 nulls show fused lobes similar to 
fused lobe (fdl) mutants in -N-acetylglucosaminidase, which removes the Mgat1-added GlcNAc 
(Leonard et al., 2006; Sakar et al., 2006). Mgat1 is also required for 3 fucose addition, a 
neuron-specific modification routinely labeled with anti-horse radish peroxidase (HRP) (Desai et 
al., 1994; Paschinger et al., 2009). Overexpression of the fucose transferase generating HRP 
glycans increases peripheral sensory neuron clustering, ventral nerve cord growth and glial 
migration (Rendic et al., 2010). Mgat1-dependent N-glycosylation occurs on many neural 
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proteins including neurotransmitter receptors, SNAREs, Fasciclins, Neuroglians, Neurexins and 
Dystroglycans (Koles et al., 2007; Muntoni et al., 2008; Sun and Xie, 2012).   
The heavily-glycosylated synaptomatrix is composed of secreted and membrane molecules 
residing at the interface between presynaptic active zones and postsynaptic receptors. 
Drosophila genetic analyses show synaptomatrix glycan modification/binding has core roles in 
structural and functional development of the neuromuscular junction (NMJ) synapse (Broadie 
et al., 2011; Dani and Broadie, 2012). Glycan-dependent synaptogenic events include 
presynaptic active zone (AZ) differentiation, postsynaptic glutamate receptor (GluR) localization 
and ECM organization within the synaptic cleft, driven by the secreted endogenous Mind-the-
Gap (MTG) lectin, for example (Dani et al., 2012; Long et al., 2008; Rushton et al., 2012). 
Synaptogenic events are regulated by bidirectional trans-synaptic signals that traverse the 
synaptomatrix, and glycosylation of both ligands and receptors alters localization and binding 
(Henriquez and Salinas, 2012; Patton, 2003). Three well-characterized trans-synaptic signals at 
the Drosophila NMJ are Wnt Wingless (Wg), BMP Glass Bottom Boat (Gbb), and Jelly Belly (Jeb) 
(Grosso et al., 2011; Kamimura et al., 2013; Rohrbough and Broadie, 2010; Tanaka et al., 2002).  
 The goal here is to test N-glycosylation requirements during NMJ synaptogenesis using 
mgat1 mutants. We found large alterations in synaptomatrix glycan composition, including 
complete lack of paucimannose glycans, fucosylated HRP epitopes and Vicia villosa (VVA) lectin 
reactivity, coupled to strongly elevated MTG expression. Null mgat1 mutants display increased 
NMJ growth (increased synapse area, branching and bouton number) and function (increased 
transmission and FM1-43 dye cycling), showing that Mgat1-dependent N-glycosylation plays 
inhibitory roles in synaptogenesis. Consistent with the hypothesis that a modified 
synaptomatrix would alter trans-synaptic signaling, Wg, Gbb and Jeb signaling ligands are all 
disrupted in the absence of mgat1 function, together with loss in synaptic recruitment of Discs 
Large (DLG) and Lethal Giant Larvae (LGL) membrane scaffolds that modulate NMJ 
synaptogenesis (Humbert et al., 2008; Staples and Broadie, 2013; Wang et al., 2011). Together, 
these results show requirements for Mgat1-dependent N-glycosylation in trans-synaptic 
signaling and synaptic localization of intracellular scaffolds driving neuromuscular 
synaptogenesis. 
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Materials and Methods  
Drosophila Genetics 
All genotypes were made in the w1118 background, with w1118 used as genetic control. 
Df(2R)BSC430 removing mgat1 was obtained from the Bloomington Drosophila Stock Center 
(Indiana University). Imprecise excision mgat11 and precise excision mgat1+9 lines have been 
characterized (Sarkar et al., 2006). Transgenic studies were done with the pan-neural elav-Gal4, 
muscle 24B-Gal4 and ubiquitous UH1-Gal4 driver lines (Brand and Perrimon, 1993; Lin and 
Goodman, 1994; Rohrbough et al., 2007) crossed to UAS-mgat1 (Sarkar et al., 2010) or UAS-
RNAi-mgat1 lines obtained from the Vienna Drosophila RNAi Center (VDRC). The Mind-the-Gap 
(MTG) cDNA fused to GFP coding sequence (UAS-MTG:GFP; Rushton et al., 2009) was placed 
into w; mgat11/Cyo-GFP to express MTG:GFP in the null background. 
 
Immunocytochemistry 
Studies were done as described previously (Rushton et al., 2012; Dani et. al., 2012). Briefly; 
wandering third instars were dissected in physiological saline consisting of 128mM NaCl, 2mM 
KCl, 4mM MgCl2, 0.2mM CaCl2, 70mM sucrose, 5mM trehalose and 5mM HEPES (pH 7.1). 
Preparations were fixed in ice-cold methanol for 5 mins (GluRIIA) or 4% paraformaldehyde for 
10 mins at room temperature (RT; all other labels). Preparations were then either processed 
with detergent (PBS + 1% BSA + 0.2% Triton X-100) for cell-permeabilized studies, or detergent-
free (PBS with 1% BSA) conditions for non-permeabilized studies. Primary antibodies used 
included: rabbit anti-horse radish peroxidase (HRP, 1:200, Sigma); mouse anti-Fasciclin 2 (Fas2, 
1:10, Developmental Studies Hybridoma Bank (DSHB), University of Iowa); rabbit anti-
Dystroglycan (Dg, 1:1000); mouse anti-glutamate receptor IIA (GluRIIA, 1:100 DSHB), rabbit 
anti-GluRIIB (GluRIIB, 1:1000; Marrus et al., 2004), and rabbit anti-GluRIIC (GluRIIC, 1:500; 
Marrus et al., 2004); mouse anti-Bruchpilot (BRP, 1:100, DSHB); rabbit anti-vesicular glutamate 
transporter  (vGlut, 1:10,000; Daniels et al., 2004); rabbit anti-Synaptobrevin (Syb, 1:500; 
Littleton et al., 1993); mouse anti-Cysteine String Protein (CSP, 1:250; Zinsmaier et al., 1990); 
rabbit anti-Synaptogyrin (GYR, 1:500; Stevens et al., 2012); mouse anti-Wingless (Wg, 1:2; 
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DSHB); rabbit anti-Glass Bottom Boat (Gbb, 1:100; Dani et al., 2012), guinea pig anti-Jelly Belly 
(Jeb, 1:2000; Lee et al., 2003); mouse anti-Discs Large (DLG, 1:200; DSHB); rabbit anti-Lethal 
Giant Larvae (LGL, 1:300; Ohshiro et al., 2000). Lectins used included: Vicia villosa agglutinin 
(VVA-Tritc, 1:200, E.Y. Laboratories); and wheat germ agglutinin (WGA, 1:200), peanut 
agglutinin (PNA, 1:250), soybean agglutinin (SBA, 1:200), Erythrina cristagalli lectin (ECL, 1:250) 
and Wisteria floribunda lectin (WFA, 1:250), all from Vector Labs. Secondary Alexa fluorophore 
antibodies (Invitrogen) used included: goat anti-mouse 488 and 568 (1:250), goat anti-rabbit 
488/568 (1:250), goat anti-guinea pig 488/568 (1:250) and streptavidin 488 (1:250). Primary 
antibodies and lectins were incubated at 4°C overnight; secondary antibodies were incubated 
at RT for 2 hrs. Dissections were mounted in Fluoromount-G (Electron Microscopy Sciences). Z-
stacks were taken with a Zeiss LSM 510 META laser-scanning confocal using 40x or 63x Plan Apo 
oil immersion objectives. Optical sections were done starting immediately above and ending 
immediately below the NMJ. Stacks were projected on the Z-axis, with NMJ signals highlighted 
and average intensity for each recorded. Intensities were quantified using ImageJ (Abramoff et 
al., 2004). 
 
Western Blotting  
Dissected wandering third instar ventral nerve cords (6) were homogenized in buffer (67mM 
NaCl, 2M Urea, 1.3% SDS, 1mM EDTA, Tris (pH 8)) and centrifuged for 30 mins at 16,000xg. 
Soluble fractions with 1X NuPage sample buffer (Invitrogen, Carlsbad, CA) and 5% 2-
mercaptoethanol were boiled for 10 mins. Samples were loaded onto 4-12% Bis-Tris SDS gels 
(Invitrogen), electrophoresed at 200V for 90 mins in 1X MES buffer and transferred to 
nitrocellulose membranes (Biorad) in 1X NuPage transfer buffer with 300mA for 1 hr at 4oC. 
Membranes were blocked in 2% BSA (Sigma) in TBS-T (10mM Tris pH 8, 150mM NaCl, 0.05% 
Tween-20) for 1 hr at RT. Rabbit anti-HRP (Sigma) [1:1000] or biotinylated VVA (EY labs) 
[1:1000] were diluted in blocking buffer and incubated for one hour at RT and washed for 5 
mins in TBS-T (x6). Mouse anti-tubulin (Sigma) [1:5000], rabbit anti-Dg [1:1000] or mouse anti-
Fas2 (34B3C2) [1:100] were diluted in blocking buffer and incubated overnight at 4oC. 
Preparations were washed for 5 mins with TBS-T (x6), and streptavidin-800 (Rockland) 
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[1:10000], goat anti-mouse 680 (Invitrogen) [1:10000] or goat anti-rabbit 800 (Rockland) 
[1:10000] were incubated for 1 hr at RT. Blots were washed for 5 mins in TBS-T (x6) and then 
imaged using an Odyssey Infrared Imaging System.  
 
Electrophysiology 
Two-electrode voltage-clamp (TEVC) electrophysiology was performed as previously reported 
(Rohrbough and Broadie, 2002). Briefly; staged larvae were glued with 3M Vetbond tissue 
adhesive (World Precision Instruments) to sylgard-coated glass coverslips, cut longitudinally 
along the dorsal midline, internal organs removed and sides glued down for neuromusculature 
access. Peripheral nerves were cut near the ventral nerve cord (VNC). Dissections and 
recordings were performed at 18°C in saline consisting of 128mM NaCl, 2mM KCl, 4mM MgCl2, 
1mM CaCl2, 70mM sucrose, 5mM trehalose and 5mM HEPES (pH 7.1). Preparations were 
imaged using a Zeiss Axioskop microscope with 40X water immersion objective. A fire-polished 
glass suction electrode was used for evoked nerve stimulation with a 0.5 ms supratheshold 
stimulus at 0.2 Hz from a Grass S88 stimulator (Rohrbough et al., 2010). Muscle 6 in abdominal 
segments 2/3 was impaled with two microelectrodes of ~15 MΩ resistance filled with 3M KCl. 
The muscle was clamped at -60 mV using an Axoclamp-2B amplifier. Excitatory junctional 
current (EJC) records were filtered at 2 kHz. To quantify EJC amplitudes, 10 consecutive traces 
were averaged and the peak of the averaged trace recorded. Clampex software was used for all 
data acquisition, Clampfit software was used for all data analysis, and GraphPad InStat 3 
software was used for statistical tests.  
 
FM1-43 Dye Imaging  
Synaptic vesicle cycling was imaged using lipophilic dye FM1-43, as previously reported (Long et 
al., 2010; Nahm et al., 2013). Briefly, for endogenous labeling, dissected preparations were 
incubated in physiological saline (1.0mM Ca2+ -43 (Invitrogen). To stop loading 
at staged intervals, the saline was replaced several times in quick succession with Ca2+-free 
saline lacking FM1-43. For evoked depolarization dye loading, preparations were stimulated 
with 90mM K+  FM1-43 for 5 mins. After imaging, preparations were unloaded with 
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the same depolarizing stimulation without FM1-43 for 2 mins. Z-stacks were taken with a Zeiss 
LSM 510 META laser-scanning confocal using a 63x water immersion objective. Fifteen slices 
were acquired and stacks projected in ImageJ. To quantify loaded/unloaded fluorescent 
intensities, five individual boutons per NMJ were outlined and average intensity measured in 
ImageJ, with muscle background intensities subtracted.  
 
Statistics 
All statistics were performed using GraphPad InStat3 software. ANOVA tests were used for all 
data sets of >3 comparisons. Student’s t-test was used for pairwise comparisons. Significance is 
presented as p≤0.05 (*), p≤0.01 (**) and p≤0.001 (***) in figures. 
 
Results 
Mgat1 shapes the glycosylated synaptomatrix of the neuromuscular junction  
  Lectins have been used to define the specialized carbohydrate environment of 
pre/postsynaptic membranes and perisynaptic extracellular space (Broadie et al., 2011; Dani 
and Broadie, 2012). For example, the widely employed anti-HRP antibody binds fucosylated N-
glycans in the presynaptic membrane, which require mgat1 for fucose modification (Sarkar et 
al., 2006). Likewise, Vicia villosa (VVA) lectin is a synaptic glycan marker at the Drosophila NMJ, 
which reportedly recognizes primarily postsynaptic Dystroglycan (Haines et al., 2007; Rushton 
et al., 2012). The endogenous Mind-the-Gap (MTG) lectin patterns the extracellular 
glycosylated synaptomatrix (Rohrbough et al., 2007), modulates trans-synaptic signaling and is 
essential for functional synaptogenesis (Rushton et al., 2009, Rohrbough and Broadie, 2010). To 
begin to define synaptogenic roles of Mgat1, we labeled the NMJ with each of these lectins in 
genetic control, mgat1 null mutants and mgat1 rescue conditions (Fig. 4). 
Wandering third instar NMJs were first probed with anti-HRP (green) compared to anti-Fasciclin 
2 (Fas2, red) in two mgat1 null conditions (mgat11/mgat11 and mgat11/Df(2R)BSC430) 
compared to w1118 genetic control (Fig. 4A). The HRP epitope robustly revealed the presynaptic 
terminal in control, but was undetectable in mutants. Phenotype rescue was assessed with 
ubiquitous UH1-Gal4 driven UAS-mgat1 in the mgat1 null background, showing complete  
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Figure 4: Loss of mgat1 activity dramatically alters the NMJ synaptomatrix. 
(A) Representative images of wandering third instar NMJs probed with anti-horse radish 
peroxidase (HRP, green) and anti-Fasciclin 2 (Fas2, red) in genetic control w1118, 
mgat11/Df(2R)BSC430 and UH1-GAL4 driven UAS-mgat1 in mgat11 null background. HRP 
labeling is undetectable in the mgat1 null, and fully restored by the genetic rescue. (B) 
Representative NMJ images of Vicia villosa (VVA, red) lectin labeling with Fas2 co-labeling 
(green) in the same genotypes. VVA labeling is undetectable in mgat1 nulls, and fully restored 
by genetic rescue. (C) Quantification of HRP and VVA intensity normalized to w1118. Statistical 
analyses with ANOVA shown as p≤0.001 (***). Sample size is >10 NMJs from >5 animals of each 
genotype. (D) Representative anti-HRP Western blot from w1118, mgat1 null and UH1-mgat1 
rescue conditions. All HRP glycans are undetectable in mgat1 null, and restored by mgat1 
rescue. The single band (*) represents bleed-through from -tubulin loading control. (E) 
Representative NMJ images of Mind-the-Gap (MTG-GFP, green) lectin co-labeled with anti-Fas2 
(red), and shown alone (MTG, white), in control (mgat1+9 precise excision) and mgat1 null. MTG 
is greatly increased in mutants (p≤0.0009; sample size: >8 NMJs, >4 animals/genotype).  
  
49 
 
recovery of the HRP signal (Fig. 4A, right). Quantification of mutants normalized to the control 
shows significant loss of HRP signal (w1118: 1.0±0.06; mgat11: 0.12±0.02, p<0.001; mgat11/Df: 
0.16±0.03. p<0.001; Fig. 4C). Anti-HRP recognizes at least 18 protein bands in Western blots 
(Fig. 4D; Desai et al., 1994). All these N-glycans are lost in mgat1 nulls and restored by UH1-
Gal4 driven UAS-mgat1 (Fig. 4D). The VVA lectin signal is similarly lost in mgat1 mutants and 
rescued with UH1-Gal4 driven UAS-mgat1 (w1118: 1.0±0.06; mgat11: 0.02±0.004, p<0.001; 
mgat11/Df: 0.04±0.01, p<0.001; Fig. 4A,C). In contrast, the endogenous MTG lectin is highly 
elevated at mgat1 null NMJs, as revealed by transgenic GFP-tagged MTG (Fig. 4E). 
Quantification of MTG-GFP within Fas2-labeled synaptic domains shows a ~70% increase in 
nulls compared to controls (mgat1+9 precise excision: 88.53±10.55; mgat11 null: 149.46±9.52; 
p<0.001). Together, these changes predict strong effects on NMJ synaptogenesis. 
 Fas2 is the best-characterized HRP-epitope protein, with critical roles in the 
development of the Drosophila NMJ (Desai, et al., 1994; Beumer et al., 2002). Similarly, 
Dystroglycan (Dg) is reportedly the primary substrate for VVA labeling at the NMJ (Haines et al., 
2007; Nakamura et al., 2010). Both HRP and VVA labeling are absent at mgat1 null NMJs (Fig. 
4), allowing analyses of the effects of loss of glycosylation on Fas2 and Dg expression and 
synaptic localization (Fig. 5). Specific antibodies against Fas2 and Dg show no detectable 
differences in protein abundance and localization at the NMJ in mgat1 nulls compared to 
controls (Fig. 5A). Western blot analyses likewise show no detectable changes in Fas2 or Dg 
protein stability or expression (Fig. 5B). Quantification of NMJ fluorescent intensities did not 
show significant changes in mgat1 nulls compared to controls for Fas2 (normalized w1118: 
1.0±0.04; mgat11: 1.03±0.05, mgat11/Df: 0.86±0.08; not significant (n.s.); Fig. 5C) or Dg (w1118: 
1.0±0.02; mgat11: 1.06±0.01, mgat11/Df: 1.04±0.04; Fig. 5C). Numerous other lectins used as 
probes, including WGA, PNA, SBA, ECL and WFA (see Methods), did not show detectable 
changes in mgat1 nulls compared to w1118 controls. Quantification of fluorescent intensities 
revealed no significant differences (data not shown). Together, these results show specific 
lectin changes at mgat1 null NMJs, with loss of HRP and VVA labeling but not other lectin labels, 
but no changes in the abundance or synaptic localization of prominent HRP- (Fas2) and VVA- 
(Dg) labeled proteins. 
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Figure 5: Fasciclin 2 and Dystroglycan are normally expressed in mgat1 nulls. 
(A) Representative NMJ images of anti-Fasciclin 2 (Fas2, red) double-labeled with anti-
Dystroglycan (Dg, green) in w1118 control and mgat11/Df mutant. (B) Representative Western 
blots double-labeled for Fas2 and HRP (left) and Dg and VVA lectin (right) in w1118 and 
mgat11/Df. Alpha tubulin is the loading control. (C) Confocal fluorescent intensity quantification 
shows no significant (n.s.) change in Fas2 or Dg at the NMJ in either homozygous mgat11 or 
mgat11/Df conditions compared to w1118. ANOVA statistical analyses were done on a sample 
size of n>16 NMJs for each genotype.  
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Development of NMJ structural overgrowth in the mgat1 null condition 
          Our recent genomic survey of glycosylation genes suggested glycan mechanisms largely 
function to restrict morphological growth during Drosophila NMJ synaptogenesis (Dani et al., 
2012). Synaptic architecture is determined by axonal growth properties, branch formation and 
the differentiation of synaptic boutons as sites of synaptic vesicle storage for neurotransmitter 
release (Broadie et al., 2011; Nahm et al., 2013). To assay these structural parameters in mgat1 
mutants, wandering third instar 6/7 NMJs were labeled with anti-Fas2 and measurements 
made of NMJ length, branch number (process with >2 boutons) and bouton number (>1m in 
diameter) in six genotypes; w1118 background control, mgat1+9 precise excision control, mgat11 
homozygous and mgat11/Df null mutants, and muscle 24B-Gal4 and ubiquitous UH1-Gal4 
driven UAS-mgat1 rescue conditions. Neuronally-driven UAS-mgat1 resulted in early 
developmental lethality, and is therefore not included. A summary of these data is shown in 
Figure 6. 
Null mgat1 mutants show a clear increase in NMJ size and structural complexity (Fig. 6A). 
Quantification of type 1 bouton number shows a highly significant increase in mutants 
normalized to control, rescued with ubiquitous but not muscle-targeted mgat1, suggesting a 
neuronal requirement (w1118: 1.0±0.03; mgat1+9: 1.02±0.08; mgat11: 1.50±0.06, p<0.001; 
mgat11/Df: 1.58±0.05 p<0.001; 24B-Gal4 driven UAS-mgat1: 1.49±0.06; UH1-Gal4 driven UAS-
mgat1: 0.97±0.08; Fig. 6B, left). Similarly, quantification of synaptic branch number shows a 
highly significant increase in mgat1 nulls, rescued only with ubiquitous mgat1 (w1118: 1.0±0.03; 
mgat1+9: 0.92±0.08; mgat11: 1.36±0.06, p<0.001; mgat11/Df: 1.26±0.03, p<0.001; UH1-Gal4 
driven UAS-mgat1: 0.89±0.06; Fig. 6B, middle). Finally, synaptic growth, quantified as 
normalized NMJ length, shows a highly significant increase in mgat1 mutants, rescue only with 
ubiquitous mgat1 (w1118: 1.0±0.03; mgat1+9: 1.14±0.09; mgat11: 1.81±0.08, p<0.001; 
mgat11/Df: 1.53±0.05 p<0.001; 24B-Gal4 driven UAS-mgat1: 1.73±0.11 p<0.001; UH1-Gal4 
driven UAS-mgat1: 0.98±0.05; Fig. 6B, right). Muscle 24B-Gal4 expression of UAS-mgat1 did not 
rescue any structural parameters, suggesting that ubiquitous or at least neuronal mgat1 
function is required to restore NMJ developmental growth and normal structural 
synaptogenesis.  
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Figure 6: Drosophila NMJ is structurally overgrown in mgat1 null mutants. 
NMJ length, axon branching and synaptic bouton number are increased in mgat1 nulls. (A) 
Representative images of wandering third instar 6/7 NMJ in genetic control (w1118), mgat11 null, 
mgat11/Df(2)BSC430 and UH1-Gal4 driven UAS-mgat1 in null background. Representative axon 
branch points (arrowheads) and boutons (arrows) are illustrated. (B) Quantification of bouton 
number, branch number and NMJ length normalized to w1118 for the mgat1+9 precise excision 
control, mgat11 homozygous null, mgat11/Df and UAS-mgat1 driven in muscle (24B-Gal4) or 
ubiquitously (UH1-Gal4) in the mgat11/Df background. All three structural parameters are 
increased in mgat1 nulls and fully rescued by ubiquitous UAS-mgat1 expression, but not 
muscle-targeted expression. Statistical analysis using ANOVA shown as p≤0.01 (**) and p≤0.001 
(***) compared to w1118. Sample size is >8 NMJ’s from >4 animals from each of the 6 genotypes 
shown.  
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Pre- and postsynaptic mgat1 roles restrict synaptic functional differentiation  
Regulation of Drosophila NMJ structural and functional synaptogenesis is often 
genetically separable, but N-glycans are causally implicated in both developmental processes 
(Broadie et al., 2011; Dani et al., 2012). However, there has been no studies to assess overall N-
glycan contributions to functional synaptic differentiation. We therefore next tested functional 
properties of mgat1 null NMJs by measuring synaptic currents using two-electrode voltage-
clamp (TEVC) recording. The motor nerve was stimulated with a glass suction electrode at 
suprathreshold levels to recruit both motor neuron inputs on muscle 6, and the excitatory 
junction current (EJC) recorded at 0.5 Hz to measure neurotransmission strength. In total, 12 
genotypes were assayed: in addition to those described above, including mgat1 nulls lacking 
maternal contribution; ubiquitous, neuron-targeted and muscle-targeted mgat1 RNAi; and 
appropriate controls for transgenic conditions. A summary of these data is shown in Figure 7. 
NMJ functional strength was clearly and consistently increased in all mgat1 loss-of-function 
conditions (Fig. 7A). Null zygotic mutants were comparable to animals lacking both maternal 
and zygotic expression, showing that a maternal contribution does not mask additional 
requirements. Mean EJC amplitudes were very significantly elevated in mgat1 mutants 
normalized to genetic control (w1118: 1.0±0.02; mgat11: 1.45±0.10, p<0.001; mgat11 without 
maternal contribution: 1.38±0.06, p<0.001; mgat11/Df: 1.40±0.05, p<0.001; Fig. 7AB). 
Ubiquitous RNAi mgat1 knockdown with UH1-Gal4 replicated this phenotype, and the elevated 
transmission was rescued by ubiquitous expression of UAS-mgat1 in mgat11/Df  (w1118: 
1.0±0.02; UH1-Gal4/+ control: 0.99±0.04; UH1-Gal4 UAS-RNAi-mgat1: 1.39±0.06, p<0.001; UH1-
Gal4 UAS-mgat1: 1.07±0.05; Fig. 7C,D). Moreover, postsynaptic mgat1 RNAi knockdown also 
increased EJC amplitude, albeit more moderately, and was rescued with postsynaptic 24B-Gal4 
UAS-mgat1 in mgat11/Df (w1118: 1.0±0.02; 24B-Gal4/+ control: 1.04±0.05; 24B-Gal4 UAS-RNAi-
mgat1: 1.29±0.06, p<0.01; Fig. 7E,D). Finally, presynaptic mgat1 RNAi also elevated 
transmission strength (w1118: 1.0±0.02; elav-Gal4/+ control: 0.96±0.05; elav-Gal4, UAS-RNAi-
mgat1: 1.51±0.11, p<0.001; Fig. 7G,H). These results reveal separable pre- and postsynaptic 
mgat1 roles limiting NMJ functional differentiation.  
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Figure 7: Strengthened synaptic functional differentiation in mgat1 null mutants. 
Neurotransmission measured using two-electrode voltage-clamp (TEVC) of stimulation-evoked 
excitatory junctional currents (EJC) at the wandering third instar muscle 6 NMJ. (A) 
Representative EJC traces recorded in 1.0mM Ca2+ from w1118, mgat11 null, mgat11 without 
maternal contribution and mgat11/Df. (B) EJC quantification for all 4 genotypes normalized to 
genetic control. Sample size is >10 animals per genotype. (C) Traces from w1118, UH1/+ control, 
UH1-GAL4 driven UAS-mgat1-RNAi and UH1-GAL4 driven UAS-mgat1 in mgat11/Df background. 
Synaptic transmission is elevated by ubiquitous RNAi knockdown and fully restored with 
reintroduction of ubiqutousUAS-mgat1. (D) EJC quantification for all 4 genotypes normalized to 
w1118. Sample size is >14 animals per genotype. (E) Traces from w1118, 24B-GAL4/+ control, 24B-
GAL4 driven UAS-mgat1-RNAi and 24B-GAL4 driven UAS-mgat1 in null background. 
Transmission elevated by postsynaptic RNAi and rescued with postsynaptic UAS-mgat1. (F) EJC 
quantification for 4 genotypes normalized to w1118. Sample size is >11 animals per genotype. (G) 
Traces from w1118, elav-GAL4/+ control and elav-GAL4 driven UAS-mgat1-RNAi.  Transmission is 
elevated with neuronal RNAi knockdown. (H) EJC quantification normalized to w1118. Sample 
size is >11 animals per genotype. Statistical analyses using ANOVA shown as p≤0.01 (**) and 
p≤0.001 (***). 
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Mgat1 regulates development of synaptic vesicle cycling properties 
 Since loss of mgat1 function increases both synaptic morphogenesis and functional 
differentiation, the next step was to determine whether the overgrown structure simply 
mediates more transmission, or if structural and functional defects are due to separable mgat1 
requirements. Synaptic vesicle (SV) cycling with FM1-43 dye measures synaptic function within 
single boutons, thus allowing a clear separation of structure and function (Long et al., 2010; 
Nahm et al., 2013). To study SV endocytosis, FM1-43 dye was loaded under endogenous activity 
conditions over a prolonged period, and in response to acute depolarization with 90mM K+ 
saline. To study SV exocytosis, NMJ terminals were depolarized a second time in the absence of 
FM1-43 to drive dye release. The ratio of loading to unloading provides a measure of SV cycling 
rate within individual synaptic boutons. A summary of these data is shown in Figure 8. 
Representative images of endogenous activity loading is shown in control and mgat11/Df NMJs 
at 1, 10 and 30 minutes in Figure 8A. Faint dye incorporation was present in boutons (arrows) 
after 1 minute loading in both genotypes, however loading occurred significantly faster in 
control compared to mutant (Fig. 8A,B). Comparing intensities over time-points revealed a 
significant decrease in mgat1 loading (1 min:  23.1±1.9 (w1118) vs. 5.0±0.3 (mgat1), p<0.0001; 10 
min: 79.5±3.5 (w1118) vs. 37.3±2.2 (mgat1), p<0.0001; 30 min: 124.8±12.6 (w1118) vs. 74.7±6.6 
(mgat1), p<0.006; Fig. 8B). This difference could represent reduced central activity in locomotor 
pattern generation, reduced SV cycling in the NMJ or elevated dye release compared to uptake. 
To distinguish these possibilities, FM1-43 dye was loaded (5 minutes) and then partially 
unloaded (2 minutes) with acute high [K+] depolarization (Fig. 8C). Representative images 
control and mgat11/Df NMJs are shown on the left, with higher magnification images of 
individual boutons shown on the right. Two defects are qualitatively apparent: mgat1 nulls 
incorporate less dye, but release dye faster (Fig. 8C). Quantification of mean fluorescent 
intensities shows decreased loading in mgat1 nulls normalized to control (w1118: 1.0±0.03; 
mgat11: 0.83±0.04, p<0.05; mgat11/Df: 0.76±0.04, p<0.001; Fig. 8D, left). More strikingly, SV 
cycling rate (unloaded/loaded fluorescent intensity) is increased in mgat1 nulls compared to 
control (w1118: 1.0±0.05; mgat11: 0.46±0.05, p<0.001; mgat11/Df: 0.37±0.03, p<0.001; Fig. 8D, 
right). Thus, mgat1 mutants exhibit altered SV cycling within individual boutons, independent  
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Figure 8: Altered NMJ synaptic vesicle cycling in the mgat1 null mutants.  
Assays of synaptic vesicle (SV) loading and cycling rates with FM1-43 dye imaging at the 
wandering third instar 6/7 NMJ. (A) Representative images of FM1-43 loading during 
endogenous activity at 1, 10 and 30 minutes. Top panels show w1118 control and bottom panels 
show mgat11/Df. Arrows indicate boutons faintly loaded at 1 minute.    (B) Fluorescence 
intensity plotted at 1, 5, 10, 15 and 30 minutes of endogenous activity. >9 animals per genotype 
used for each time point. (C) Representative NMJ images after FM1-43 loading with 90mM K+ 
for 5 minutes and unloading for 2 minutes. Top panels show w1118 and bottom panels show 
mgat11/Df, with increased SV turnover indicated by reduced intensity after unloading. Right 
panels show high magnification images of loaded/unloaded boutons. (D) Quantification of 
loading and ratio of unloaded/loaded fluorescent intensities for w1118, mgat11 homozygous null 
and mgat11/Df.  Statistical analyses compared to genetic control w1118 using ANOVA shown as 
p≤0.05 (*), p≤0.01 (**) and p≤0.001 (***). Sample size is >18 NMJs for each genotype. 
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of the increased bouton number, with a strong increase in cycling rate in response to acute 
depolarization.  
 
Selective loss of pre-and postsynaptic components in mgat1 null mutants 
Functional differentiation of the NMJ requires recruitment and organization of presynaptic SV 
cycle proteins and active zone (AZ) release sites, and postsynaptic glutamate receptors (GluRs; 
Featherstone et al., 2005; Long et al., 2008; Richmond and Broadie, 2002). N-glycosylation may 
be important for localization and maintenance of these key proteins during synaptogenesis, 
hypothesized to be dependent on Mgat1 function (Dani et al., 2012; Kwon and Chapman, 
2012). We therefore next conducted a thorough confocal microscopy expression survey of 
synaptic proteins in the mgat1 null condition to test for changes in presynaptic and 
postsynaptic composition. Most proteins were unchanged in mgat1 mutants, and only a few 
molecular changes were identified. A summary of these results is shown in Figure 9. 
Postsynaptic GluRs are believed to form tetramers composed of 3 essential subunits (GluRIIC-E) 
and a single variable subunit (GluRIIA or B) generating two distinct GluR functional classes 
(Featherstone, et al., 2005; Qin et al., 2005). To assay these receptor classes, we probed control 
and mgat1 null NMJs with antibodies specific for GluRIIA, B and C subunits. There was no 
detectable change in the overall expression of total GluRs (labeled with the essential GluRIIC) or 
the GluRIIA-class receptors in the mgat1 null condition (data not shown). In contrast, there was 
a clear and obvious decrease in GluRIIB-class receptors in mgat1 nulls, both at low level 
magnification of the entire NMJ and in higher resolution images of individual synaptic boutons 
(Fig. 9A). Quantitative measures of fluorescent intensity show a highly significant decrease in 
GluRIIB labeling in mgat11/Df normalized to the genetic control (w1118: 1.0±0.09; mgat11/Df: 
0.73±0.04, p<0.01; Fig. 9D, left). This selective loss of GluRIIB shows that this one receptor class 
alone appears dependent on Mgat1 function. 
The presynaptic apparatus includes key AZ protein Bruchpilot (BRP), V/T-SNARES of the core 
SNARE complex, and a host of SV associated and integral proteins regulating the SV cycle 
(Chapman, 2002; Hallermann et al., 2010). We assayed a wide range of these presynaptic 
proteins for changes in mgat1 null mutants, and found that all did not detectably change, with  
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Figure 9: Pre- and postsynaptic component recruitment reduced at mgat1 NMJs. 
Null mgat1 mutants show decreased postsynaptic glutamate receptor type IIB (GluRIIB) and 
presynaptic active zone Bruchpilot (BRP), but are unchanged for multiple other synaptic 
components. (A-C) Representative NMJ images for GluRIIB (A, green), BRP (B, red) and the 
vesicular glutamate (V-Glut) transporter (C, red) in genetic control w1118 and mgat11/Df 
mutants. High magnification images of synaptic boutons shown below. (D) Quantification of 
fluorescent intensities for GluRIIB (n>28), BRP (n>38), V-Glut (n>12) and Synaptobrevin (Syb; 
n>16) normalized to w1118. V-Glut and Syb exhibit no change, indicating similar synaptic vesicle 
related density in control and mutant. Statistical analyses using students t-test for each 
pairwise comparison, with significance shown as p≤0.05 (*), p≤0.01 (**) and p≤0.001 (***). 
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only a single exception. The BRP punctae marking AZs were clearly decreased in mgat1 
mutants, both in whole NMJs and in high magnification images of synaptic boutons (Fig. 9B). 
Quantification of BRP labeling intensities showed a significant decrease in mgat11/Df 
normalized to control (w1118: 1.0±0.07; mgat11/Df: 0.80±0.05, p<0.05; Fig. 9D). In contrast, 
other presynaptic components (e.g. Synaptotagmin, Cysteine String Protein (CSP), Synaptogyrin 
(GYR), etc.) were not detectably altered in mgat1 nulls (data not shown). As exemplars of these 
negative data, we show vesicular glutamate transporter (V-Glut) and V-SNARE Synaptobrevin 
(Fig. 9D). The selective loss of just BRP shows a focused presynaptic requirement for Mgat1 
function. 
 
Multiple trans-synaptic signaling pathways altered in mgat1 null mutants 
Active zone (i.e. BRP) and class-specific GluR (i.e. GluRIIB) recruitment are both dependent on 
tightly regulated trans-synaptic signaling between pre- and postsynaptic cells during 
synaptogenesis (Dani et al., 2012; Margues, 2005; Rohrbough et al., 2013). Moreover, both 
trans-synaptic signaling pathway components and the synaptomatrix they traverse are highly 
glycosylated, and it is known that glycan mechanisms play key roles in the regulation of this 
developmental communication (Rohrbough and Broadie, 2010; Rohrbough et al., 2013). We 
therefore hypothesized that mgat1 mutants would manifest defects in bidirectional trans-
synaptic signals. To test this idea, we assayed signaling ligands for three well-characterized 
trans-synaptic pathways; 1) anterograde Wnt Wingless (Wg), 2) retrograde BMP Glass Bottom 
Boat (Gbb), and 3) newly-defined ligand Jelly Belly (Jeb). Representative NMJ images and the 
compiled quantification for these studies are shown in Figure 10. 
Well-characterized antibodies for all 3 signaling ligands were used to label wandering third 
instar NMJs, comparing fluorescent intensities within the synaptic domain (dotted white 
outlines) in mgat11/Df null normalized to the w1118 genetic control (Fig. 10). The Wg signal was 
obviously increased in mutants (Fig. 10A, middle), and quantification of fluorescent intensity 
confirmed a significant elevation (w1118: 1.0±0.10; mgat11/Df: 1.56±0.16, p<0.001; Fig. 10A, 
right). In contrast, the Gbb signal was clearly reduced and poorly localized to the synaptic 
domain in mutants (Fig. 10B, middle), and likewise significantly decreased in quantified  
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Figure 10: Multiple trans-synaptic signaling pathways altered in mgat1 null mutant. 
Assays of three well-characterized NMJ trans-synaptic signals: Wingless (Wg), Glass Bottom 
Boat (Gbb) and Jelly Belly (Jeb). (A) Representative NMJ images of Wg (red) double-labeled with 
HRP (blue), and shown alone (Wg, white). High magnification bouton comparison of genetic 
control (w1118) and mgat11/Df. Right: Quantification of relative fluorescent intensity reveals 
increased Wg in mutant. (B) Representative images of Gbb (green) double-labeled with HRP 
(blue), and shown alone (Gbb, white). High magnification bouton comparison of w1118 and 
mgat11/Df. Right: Quantification shows decreased Gbb in mutant. (C) Representative NMJ 
images of Jeb (green) double-labeled with HRP (blue), and shown alone (Jeb, white). High 
magnification bouton comparison of w1118 and mgat11/Df. Right: Quantification shows 
decreased Jeb in mutant. Fluorescent intensities measured within the NMJ domain (white 
dotted line), normalized to genetic control w1118. Statistical analyses were done using student’s 
t-test for pairwise comparisons, with significance shown as p≤0.01 (**) and p≤0.001 (***). The 
sample size is n>18 NMJs for each label and each genotype.  
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intensity (w1118: 1.0±0.08; mgat11/Df: 0.55±0.08, p<0.001; Fig. 10B, right). The third signal Jeb 
was similarly decreased in mgat11/Df compared to control (w1118: 1.0±0.07; mgat11/Df: 
0.63±0.07 p<0.01; Fig. 10C). These results reveal a differential Mgat1 role in modulating trans-
synaptic signaling, with increased abundance of Wg ligand and decreases in both Gbb and Jeb 
ligands. A primary role of trans-synaptic signaling is to recruit synaptic scaffolds which, in turn, 
bind synaptic proteins to seed the process of synaptogenesis. 
 
Loss of key synaptic scaffolds driving synaptogenesis in mgat1 null mutants 
Discs Large (DLG) is a particularly well-characterized synaptic scaffold at the Drosophila NMJ, 
which is modulated downstream of Wg, Gbb and Jeb trans-synaptic signaling and, in turn, 
drives the appropriate recruitment of synaptic proteins including cell adhesion molecules, ion 
channels and GluRIIB-containing receptors (Chen and Featherstone, 2005; Marqués, 2005; 
Marrus et al., 2004). In addition, we have just recently defined Lethal Giant Larvae (LGL) as 
another key synaptic scaffold, which presynaptically facilitates the assembly of BRP-containing 
active zones to regulate SV cycling, and postsynaptically regulates GluR subunit composition 
(Staples and Broadie, 2013). We hypothesized that, downstream of Mgat1-dependent changes 
in trans-synaptic signaling, defects in recruiting these synaptic scaffolds could explain changes 
in pre/postsynaptic molecular composition. To test this idea, we imaged DLG and LGL scaffolds 
at the wandering third instar NMJ, comparing mgat1 nulls to genetic controls. A summary of 
these data is shown in Figure 11. 
 The DLG scaffold is expressed in both pre- and postsynaptic compartments, but is most 
apparent in the subsynaptic reticulum (SSR) overlapping with postsynaptic glutamate receptors 
(Fig. 11A). DLG levels are clearly and strongly decreased in mgat1 null mutants compared to 
controls. When intensity levels were quantified, there was a very significant decrease in 
mutants normalized to genetic control (w1118: 1.0±0.08; mgat11: 0.66±0.06, p<0.01; Fig. 11C, 
top). Similarly, the LGL scaffold is present in the Fas2-labeled NMJ terminals in both presynaptic 
boutons and the postsynaptic domain, with clearly higher levels of expression in genetic control 
compared to the mgat1 null condition (Fig. 11B). Quantification of fluorescent intensity shows a 
highly significant decrease in LGL (w1118: 1.0±0.07; mgat11: 0.50±0.06, p<0.001; Fig. 11C,  
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Figure 11: Synaptic scaffolds DLG and LGL reduced in the mgat1 null mutants.  
Imaging of Discs Large (DLG) and Lethal Giant Larvae (LGL) synaptic scaffolds at the wandering 
third instar NMJ. (A) Representative images of DLG (red) co-labeled with glutamate receptor 
type IIC (GluRIIC, green), with higher magnification boutons in side panels. (B) Representative 
images of LGL (red) co-labeled with Fas2 (green), with high magnification boutons in side 
panels. (C) Quantification of DLG fluorescent intensity (top: mgat11 (n=15), w1118 (n=22)) and 
LGL fluorescent intensity (bottom: mgat11 (n=12), w1118 (n=12)). Statistical analyses done using 
student’s t-test for pairwise comparisons, with significance shown as p≤0.01 (**) and p≤0.001 
(***) 
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bottom). LGL and DLG scaffolds are both known to regulate active zone and glutamate receptor 
composition, so changes in their abundance and localization are likely to be causal in Mgat1-
dependent changes in NMJ synaptogenesis.  
 
Discussion 
We began with the hypothesis that disruption of synaptomatrix N-glycosylation would 
alter trans-synaptic signaling underlying NMJ synaptogenesis (Dani and Broadie, 2012). Mgat1 
loss transforms the synaptomatrix glycan environment. Complete absence of the HRP epitope, 
-3-fucosylated N-glycans, is expected as it requires Mgat1 activity: key HRP epitope synaptic 
proteins include Fasciclins, Neurotactin and Neuroglian, among others (Desai et al., 1994; 
Paschinger et al., 2009). We show that HRP epitope modification of the key synaptogenic 
regulator Fasciclin 2 is not required for stabilization or localization, suggesting a role in protein 
function. On the other hand, complete loss of VVA lectin synaptomatrix labeling is surprising 
because the epitope is a terminal -GalNAc (Martin, 2003). This result suggests that the N-
glycan LacdiNAc is enriched at the NMJ, and that the terminal GalNAc expected on O-
glycans/glycosphingolipids may be present on N-glycans in this synaptic context. Importantly, 
VVA labels Dystroglycan and loss of Dystroglycan glycosylation blocks extracellular ligand 
binding and complex formation in Drosophila (Haines et al., 2007; Nakamura et al., 2010), and 
causes muscular dystrophies in humans (Ervasti et al., 1997; Muntoni et al., 2008; Tran et al., 
2012). This study shows that VVA-recognized Dystroglycan glycosylation is not required for 
protein stabilization or synaptic localization, but did not test functionality or complex 
formation, which likely requires Mgat1-dependent modification. Conversely, the secreted 
endogenous lectin MTG is highly elevated in mgat1 null synaptomatrix, likely owing to 
attempted compensation for complex and hybrid N-glycan losses that serve as MTG binding 
sites. MTG binds GlcNAc in a calcium-dependent manner and pulls down a number of HRP-
epitope proteins by immunoprecipitation (Rushton et al., 2012), although the specific proteins 
have not been identified. It will be of interest to perform immunoprecipitation on mgat1 
samples to identify changes in HRP bands. Importantly, MTG is critical for synaptomatrix glycan 
patterning and functional synaptic development (Rohrbough et al., 2007). MTG regulates VVA 
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synaptomatrix labeling (Rushton et al., 2009), suggesting a mechanistic link between the VVA 
and MTG changes in mgat1 mutants. The MTG elevation observed in mgat1 nulls provides a 
plausible causative mechanism for strengthened functional differentiation (Rohrbough and 
Broadie, 2010; Rushton et al., 2012).  
Consistent with our recent glycosylation gene screen findings (Dani et al., 2012), mgat1 nulls 
exhibit increased synaptic growth and structural overelaboration. Therefore, complex and 
hybrid N-glycans overall provide a brake on synaptic morphogenesis, although individual N-
glycans may provide positive regulation. Likely players include Mgat1-dependent HRP-epitope 
proteins (e.g. Fasciclins, Neurotactin, Neuroglian), and Position Specific (PS) integrin receptors 
and their ligands, all of which are heavily glycosylated and have well-characterized roles 
regulating synaptic architecture (Beumer et al., 1999; Rushton et al., 2009; Beck et al., 2012; 
Enneking et al., 2013). An alternate hypothesis is that mgat1 phenotypes may result from the 
presence of high-mannose glycans on sites normally carrying complex/hybrid structures 
(Schachter, 2010), suggesting possible gain-of-function rather than loss-of-function of specific 
N-glycan classes. NMJ branch and bouton number play roles in determining functional strength 
(Thomas and Sigrist, 2012), although active zones and GluRs are also regulated independently 
(DiAntonio, 2006). Thus, the increased functional strength could be caused by increased 
structure at mgat1 null NMJs. However, muscle-targeted UAS-mgat1 rescues otherwise mgat1 
null function, but has no effect on structural defects, demonstrating that these two roles are 
separable. On the other hand, presynaptic mgat1 RNAi also causes strong functional defects, 
showing there is additionally a presynaptic requirement in functional differentiation. Neuron-
targeted mgat1 causes lethality, indicating that Mgat1 levels must be tightly regulated, but 
preventing independent assessment of mgat1 presynaptic rescue of synaptogenesis defects.  
 Presynaptic glutamate release and postsynaptic glutamate receptor responses drive 
synapse function. Using lipophilic dye to visualize SV cycling, we found mgat1 null mutants 
endogenously cycle less than controls, but have greater cycling capacity upon depolarizing 
stimulation. The endogenous cycling defect is consistent with the sluggish locomotion of mgat1 
mutants (Sakar et al., 2006), whereas the elevated stimulation-evoked cycling is consistent with 
electrophysiological measures of neurotransmission. Similarly, mutation of dPOMT1, which 
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glycosylates VVA-labeled Dystroglycan, decreases SV release probability (Wairkar et al., 2008), 
although dPOMT1 adds mannose not GalNAc. Null mgat1 mutants display no change in SV cycle 
components (e.g. Synaptobrevin, Synaptotagmin, Synaptogyrin, etc.), but exhibit reduced 
expression of the key active zone component Bruchpilot (Wagh et al., 2006; Kittel et al., 2006). 
Other examples of presynaptic glycosylation requirements include the Drosophila Fuseless 
(Fusl) glycan transporter, which is critical for Cacophony (Cac) voltage-gated calcium channel 
recruitment to active zones (Long et al., 2008), and the mammalian GalNAc transferase 
(Galgt2), whose over-expression causes decreased active zone assembly (Martin, 2003). 
Postsynaptically, mgat1 nulls show specific loss of GluRIIB-containing receptors. Similarly, 
dPOMT1 mutants exhibit specific GluRIIB loss (Wairkar et al., 2008), although dystroglycan nulls 
display GluRIIA loss (Bogdanik et al., 2008). Selective GluRIIB loss in mgat1 nulls may drive 
increased neurotransmission owing to channel kinetics differences in GluRIIA vs. GluRIIB 
receptors (DiAntonio et al., 1999).  
Bi-directional trans-synaptic signaling regulates NMJ structure, function and 
pre/postsynaptic composition (Dani et al., 2012; Enneking et al., 2013; Muller and Davis, 2012). 
This intercellular signaling requires ligand passage through, and containment within, the 
heavily-glycosylated synaptomatrix (Dani and Broadie, 2012; Martin, 2003), which is strongly 
compromised in mgat1 mutants. In testing three well-characterized signaling pathways, we 
found that Wg accumulates, whereas both Gbb and Jeb are reduced in the mgat1 null 
synaptomatrix. Wg has two N-glycosylation sites, but these do not regulate ligand expression 
(Tang et al., 2012), suggesting Wg buildup occurs due to lost synaptomatrix N-glycosylation. 
Importantly, Wg overexpression increases NMJ bouton formation similar to the phenotype of 
mgat1 nulls (Ataman et al., 2008; Korkut et al., 2009), suggesting a possible causal mechanism. 
Gbb is predicted to be N-glycosylated at four sites, but putative glycosylation roles have not yet 
been tested. Importantly, Gbb loss impairs presynaptic active zone development similar to 
mgat1 nulls (McCabe et al., 2003; Nahm et al., 2010), suggesting a separable causal mechanism. 
Jeb is not predicted to be N-glycosylated, indicating Jeb loss is caused by lost synaptomatrix N-
glycosylation. Importantly, we have just recently shown that loss of Jeb signaling increases 
functional synaptic differentiation similar to mgat1 nulls (Rohrbough et al., 2013). In addition, 
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jeb mutants exhibit strongly suppressed NMJ endogenous activity, similar to the reduced 
endogenous SV cycling in mgat1 nulls (Rohrbough and Broadie, 2010). Moreover, the MTG 
lectin negatively regulates Jeb accumulation in NMJ synaptomatrix (Rohrbough and Broadie, 
2010), consistent with elevated MTG causing Jeb down-regulation in mgat1 nulls.  
Trans-synaptic signaling drives recruitment of scaffolds that, in turn, recruit pre- and 
postsynaptic molecular components (Ataman et al., 2006; Koles et al., 2012). Specifically, DLG 
and LGL scaffolds regulate the distribution and density of both active zone components (e.g. 
BRP) and postsynaptic GluRs (Chen and Featherstone, 2005; Staples and Broadie, 2013), and 
both of these scaffolds are reduced at mgat1 null NMJs. Importantly, dlg mutants display 
selective loss of GluRIIB, with GluRIIA unchanged, similar to mgat1 nulls (Chen and 
Featherstone, 2005), suggesting a causal mechanism. Moreover, lgl mutants display both a 
selective GluRIIB impairment as well as reduction of BRP aggregation in active zones, similar to 
mgat1 nulls (Staples and Broadie, 2013), suggesting a separable involvement for this synaptic 
scaffold. DLG and LGL are known to interact in other developmental contexts (Humbert et al., 
2008), indicating a likely interaction at the developing synapse. Although synaptic ultrastructure 
has not been examined in lgl mutants, dlg mutants exhibit impaired NMJ development, 
including a deformed subsynaptic reticulum (SSR; Lahey et al., 1994). These synaptogenesis 
requirements predict similar ultrastructural defects in mgat1 mutants, albeit presumably due to 
the combined loss of both DLG and LGL scaffolds. Our future work will focus on electron 
microscopy analyses to probe N-glycosylation mechanisms of synaptic development.  
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Translational Impact  
1) Clinical Issue: The rapidly expanding congenital disorders of glycosylation (CDG) disease 
family results from mutation of genes encoding glycosylation pathway proteins, which 
drive the addition of carbohydrate moieties to proteins. The most common CDG, CDG-Ia 
or PMM2-CDG, is caused by loss of phosphomannomutase type 2 (PMM2), which 
converts mannose-6-phosphate into mannose-1-phosphate. This obligatory step is 
required for all N-linked glycosylation, an important and widespread glycan modification 
of extracellular proteins, which aids in many aspects of protein localization and function. 
Human CDG-Ia patients present with severe neurological impairments, including loss of 
coordinated movement and intellectual disability, and are often concomitantly afflicted 
with multi-organ dysfunction, infection and injury also contributing to reduced lifespan. 
Here, we generate the first Drosophila CDG-Ia disease model, showing phenotypes that 
strongly parallel patient neurological symptoms and compromised longevity. Previous 
animal models have revealed important aspects of CDG-Ia disease progression in 
neurodevelopment and cellular signaling, but are limited by the inability to study tissue-
specific reduction of PMM2 function in a temporally and spatially-controlled manner. 
These capacities are provided in this Drosophila disease model, which allows assessment 
of developmental, cell type-specific PMM2 involvement.    
2) Results: The new Drosophila PMM2-CDG disease model recapitulates the characteristic 
phenotypes of the human disease state. Using both pmm2 null mutants and targeted 
RNAi knockdown, we demonstrate early lethality, severe loss of coordinately movement 
and reduced/dysregulated glycosylation. We focus on the neuromuscular junction (NMJ) 
that drives movement to reveal reduced levels of synaptic glycosylation coupled to 
structural overelaboration and functional strengthening. Based on phenotypes, we 
hypothesized that compromised NMJ synaptic glycosylation would alter matrix 
metalloproteinase (MMP) pathways known to modulate Wnt intercellular signaling. In 
testing this hypothesis, we discovered depressed MMP expression at the NMJ resulting 
in reduced Wnt Wingless (Wg) trans-synaptic signaling that modulates synaptic 
development and function.  
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3) Implications and future directions: Increasing evidence highlights the importance of 
glycosylation in neural development and function. The majority of CDG patients present 
with severe neurological symptoms; however, the causes remain very poorly 
understood. Here, we present a new Drosophila CDG-Ia model identifying a range of 
phenotypes that closely resemble human patient symptoms. This new model will allow 
in-depth studies to discover underlying causative mechanisms, decipher them, and 
ultimately inform drug design. The MMP and Wnt changes identified here represent 
candidate drug targets for treating CDG-Ia neurological symptoms. Discoveries aided by 
the relative high speed of Drosophila studies combined with the powerful, ever-
expanding Drosophila genetic toolkit will open up new avenues for CDG-Ia therapeutic 
intervention. 
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Abstract  
Congenital disorders of glycosylation (CDGs) constitute a rapidly growing family of 
human diseases resulting from heritable mutations in genes driving production and 
modification of glycoproteins. The resulting symptomatic hypoglycosylation causes 
multisystemic defects that include severe neurological impairments, revealing a particularly 
critical requirement for tightly regulated glycosylation in the nervous system. The most 
common CDG, CDG-Ia or PMM2-CDG, arises from phosphomannomutase type 2 (PMM2) 
mutations. Here, we report the generation and characterization of the first Drosophila PMM2-
CDG model. CRISPR-generated Drosophila pmm2 null mutants display severely disrupted 
glycosylation and early lethality, while RNAi-targeted neuronal PMM2 knockdown results in a 
strong shift in pauci-mannose glycan abundance, progressive incoordination and later lethality, 
closely paralleling human CDG-Ia symptoms of shortened lifespan, movement impairments and 
defective neural development. Analyses of the well-characterized Drosophila neuromuscular 
junction (NMJ) reveal synaptic glycosylation loss accompanied by structural architecture and 
functional neurotransmission defects. NMJ synaptogenesis is driven by intercellular signals 
traversing an extracellular synaptomatrix co-regulated by glycosylation and matrix 
metalloproteinases (MMPs). Specifically, Wnt Wingless (Wg) trans-synaptic signaling depends 
on the heparan sulfate proteoglycan (HSPG) co-receptor Dally-like protein (Dlp), which is 
regulated by synaptic MMP activity. Loss of synaptic MMP2, Wg ligand, Dlp co-receptor and 
downstream trans-synaptic signaling occurs with PMM2 knockdown. Taken together, this 
Drosophila CDG disease model provides a new avenue for the dissection of cellular and 
molecular mechanisms underlying neurological impairments and a means to discover and test 
novel therapeutic treatment strategies. 
 
 
 
 
 
 
89 
 
Introduction 
 Congenital disorders of glycosylation (CDGs) caused by mutation of genes encoding 
glycosylation pathway proteins are classified into two categories (Freeze et al., 2015): CDG-I 
disease states include defects in carbohydrate production, lipid-linked oligosaccharide (LLO) 
formation and attachment of glycan chains to amino acids; CDG-II disease states include defects 
in modification/maturation of glycan chains after protein attachment. The most common CDG 
is a CDG-I, called CDG-Ia or PMM2-CDG, resulting from mutations in phosphomannomutase 2 
(PMM2) converting mannose-6-phosphate to mannose-1-phosphate, the obligatory precursor 
for GDP-mannose production and N-linked glycosylation (Andreotti et al., 2014; Freeze et al., 
2014; Freeze et al., 2015). Since the first patient in 1980, >100 different mutations in >1000 
CDG-Ia patients have been characterized (Freeze et al., 2014; Haeuptle and Hennet, 2009; 
Jaeken, 2013; Jaeken et al., 1980; Yuste-Checa et al., 2015). CDG-Ia infant mortality is ~20% in 
the first year, with patients manifesting subsequent increased susceptibility to organ failure, 
infection and injury (Grunewald, 2009). CDG-Ia patients present with a spectrum of 
neurological symptoms (Jaeken, 2013), ranging from severe neurological impairments with 
early death, to mild defects with slight psychomotor delay (Grunewald, 2009; Marquardt and 
Denecke, 2003). To date, no effective treatments are available, with the only treatment option 
being symptom management (Grunewald, 2009; Monin et al., 2014; Stefanits et al., 2014).  
 CDG-Ia modeling is critical for molecular and cellular studies. The initial mouse PMM2 
knockout model has been of limited use owing to early embryonic lethality (Thiel et. al., 2006). 
Heteroallelic combination of two PMM2 mutations allows partial enzymatic activity, protracted 
embryonic survival and has demonstrated potential maternal dietary intervention in treatment 
(Schneider et al., 2011). Increased lifespan occurred with mannose feeding prenatally and 
during gestation, reportedly allowing offspring to develop past critical periods of PMM2-
dependent glycan requirement (Schneider et al., 2011; Thiel et al., 2006). Unfortunately, these 
results have thus far not been successfully replicated in patient trials, where postnatal oral and 
intravenous mannose administration failed to improve serum protein glycosylation levels 
(Kjaergaard et al., 1998; Mayatepek and Kohlmuller, 1998). A subsequent zebrafish model 
established via PMM2 morpholino knockdown revealed increased motor neuron number, 
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altered cranial development, reduced motility and altered glycan profiles (Cline et al., 2012). 
Most recently, a similar Xenopus morpholino knockdown model demonstrated strong reduction 
in Wnt signaling, revealing a PMM2 requirement in intercellular communication (Himmelreich 
et al., 2015). These models have been valuable, but have limitations of morpholino-based 
approaches with inadequate targeting and concerns about the temporal maintenance of 
knockdown (Schulte-Merker and Stainier, 2014). We therefore set out to develop a Drosophila 
PMM2-CDG disease model. 
 The Drosophila genome encodes >70% of human disease genes (Reiter et al., 2001), 
including most linked to glycan-related disorders (Dani et al., 2012; Dani et al., 2014). The 
human N-linked glycome is more expansive, with higher levels of complex and hybrid branched 
forms (Katoh and Tiemeyer, 2013), but the N-glycosylation pathway is very highly conserved, 
with well-mapped glycan profiles and the Drosophila genetic toolkit allowing sophisticated 
manipulation (Altmann et al., 2001; Sarkar et al., 2006). For neurological impairments (Freeze, 
2006; Freeze et al., 2015; Jaeken, 2013; Martin, 2003), Drosophila provides a host of 
anatomical, electrophysiological and behavioral assays for neural development and function 
(Dani el al., 2014; Gatto and Broadie, 2011; Jumbo-Lucioni et al., 2014; Parkinson et al., 2013). 
In particular, our glycomic RNAi screen uncovered a common role for glycosylation restricting 
the structure and function of the neuromuscular junction (NMJ) synapse (Dani et al., 2012). 
Subsequent work on screen hits, including heparan sulfate proteoglycan (HSPG) sulfotranserase 
(hs6st)/sulfatase (sulf1), UDP-GlcNAc:α-3-D-mannoside-β1,2-N-acetylglucosaminyl-transferase I 
(mgat1), α-N-acetylgalactosaminyltransferase (pgant), galactose-1-phosphate uridyl-
transferase (galt) and related pathways (Dani et al., 2012; Dani et al., 2014; Jumbo-Lucioni et 
al., 2014; Parkinson et al., 2013), has shown disruption of trans-synaptic signaling to be a 
common root cause of the compromised NMJ synaptogenesis underlying movement 
phenotypes. 
 In this study, we generate a Drosophila CDG-Ia disease model. We show that Drosophila 
pmm2 is highly conserved and manipulate gene function by making mutants with CRISPR/Cas9 
genome editing and tissue-targeted transgenic RNAi. As in human CDG-Ia patients, Drosophila 
pmm2 loss-of-function (LOF) mutants exhibit reduced lifespan and psychomotor retardation 
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proportional to the degree of PMM2 reduction. We show striking impacts on the N-linked 
glycome: globally in null mutants, neurally in tissue-targeted RNAi knockdown and locally at the 
NMJ synapse. At the NMJ, targeted pre- and postsynaptic PMM2 knockdown reveals 
architectural overelaboration, and concurrent reduction on both sides of the synapse strongly 
increases neurotransmission strength. PMM2 loss strongly impairs the synaptic matrix 
metalloproteinase (MMP) pathway regulating HSPG co-receptor Dally-like protein (Dlp) to 
modulate Wnt Wingless (Wg) trans-synaptic signaling (Dani et al., 2012; Dear et al., 2016; 
Freidman et al., 2013). Consistently, PMM2 knockdown reduces Wg, Dlp and the Frizzled 
Nuclear Import (FNI) pathway. These results suggest a PMM2-dependent extracellular 
proteinase mechanism modulates Wnt signaling during NMJ synaptogenesis, which underlies 
coordinated movement and maintained viability. This new Drosophila model should lead to 
novel therapeutic treatments for CDG-Ia.  
 
Results 
Degree of Drosophila PMM2 loss determines lifespan duration 
 Human pmm2 contains 8 exons compared to the Drosophila CG10688 pmm2 single 
reading frame (Fig. 12A), making genetic manipulation and expression studies more amenable. 
Simplified site-directed CRISPR mutagenesis targeted at one exon reduces the possibility of 
truncated exons maintaining partial function. Human PMM2 contains 12 active sites that 
coordinately bind the substrate, mannose-6-phosphate, and convert it to mannose-1-
phosphate (Andreotti et al., 2014; Silvaggi et al., 2006). Drosophila PMM2 shows 100% 
conservation of these 12 active sites (Fig. 12A, red) and identifies numerous additional regions 
of high 90-100% conservation (Fig. 12A, green). Overall, Drosophila PMM2 displays 56% amino 
acid identity compared to human PMM2 (Fig. 12A). To characterize PMM2 requirements, we 
first made null mutants using CRISPR/Cas9 genome editing directed at both 5’ and 3’ ends of 
Drosophila pmm2 (Fig. 12A; Gratz et al., 2013). A total of 15 mutations were produced, all 
verified with direct sequencing: 8 frameshifts, 4 insertions, 2 deletions and 1 missense 
mutation. Two pmm2 null frameshift mutations were selected for subsequent behavioral, 
functional and molecular studies, hereafter referred to as pmm2FS1 and pmm2FS2.  
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Figure 12  
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Figure 12: Drosophila PMM2 levels determine lifespan and coordinated movement ability.  
A) Comparison of human and Drosophila pmm2 genes. Human pmm2 contains 8 exons (black 
boxes) compared to the single reading frame in Drosophila. Highly conserved active sites (red) 
and other regions of high identity (90-100%, green) are depicted. CRISPR-generated null 
mutants were made at both 5’ and 3’ ends of pmm2 (arrows). B) Larval lifespan of null mutants 
(pmm2FS1, pmm2FS1/Df and heteroallelic pmm2FS1/FS2), and two driven RNAi lines (RNAi42956 and 
RNAi107619) compared to controls (left). Adult lifespan with targeted neural (elav-Gal4) and 
muscle (24B-Gal4) pmm2 RNAi compared to controls (right). C) Examples of wing posture with 
neural pmm2 RNAi. D) Behavioral assays: larval locomotion on apple juice plates towards edge 
yeast attractant (left); adult negative geotaxis climbing to 2 cm height (middle), and adult 
horizontal locomotion for flies with wings removed exiting a 4 cm ring (right). E) Normalized 
quantification of 1st (left) and 3rd instar (right) larval locomotion (peristaltic waves/second) in 
genotypes shown.  F) Quantification of adult negative geotaxis as percent animals climbing to 
2cm height at 5 (left) and 10 (right) seconds. G) Quantification of adult horizontal locomotion as 
time to exit 4cm ring). Significance: p<0.0001 (****). Sample sizes: n>17 animals/genotype.   
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Two independent UAS-RNAi lines (Bloomington Drosophila Stock Center #42956 and 
Vienna Drosophila Resource Center v107619) were used to differentially reduce pmm2 levels. 
Quantitative PCR (qRT-PCR) with ubiquitous (UH1-Gal4) expression shows both RNAi lines 
knockdown pmm2 transcripts by >77%, a significant (p<0.001) reduction compared to UH1-
Gal4/+ transgenic controls. Of the two lines, 42956 is significantly more effective than 107619 
in reducing pmm2 levels (UH1>RNAi107619, 1.57±0.10; UH1>RNAi42956, 1.27±0.10; n=15, p=0.016) 
compared to control (UH1-Gal4/+, 7.00±0.79, n=15). Moreover, at 50% lethality  of ubiquitous 
pmm2 knockdown (42956) (Fig. 12B), pmm2 levels in UH1-Gal4/+ controls show a sharp 
increase (1st instar, 1.40±0.15, n=8; 2nd instar 7.00±0.79, n=15), which is paralleled by the 
surviving ubiquitous pmm2 knockdown (107619), permitting higher levels of maintained pmm2 
expression. The strong (42956) and weak (107619) PMM2 knockdown phenotypes are likely the 
result of the significant differences in transcript levels.   
Null pmm2 mutants, heteroallelic combinations and mutants over deficiency all show 
identical early larval lethality during the late 1st to early 2nd instar transition (Fig. 12B). Half-time 
survival (HTS) is similar (e.g. pmm2FS1 HTS 51 hours post-hatching (hph), n=73; pmm2FS1/Df HTS 
46 hours post-hatching (hph), n=79; pmm2FS2/Df HTS 51 hours post-hatching (hph), n=84; 
pmm2FS1/pmm2FS2 HTS 52 hph, n=75). Ubiquitous pmm2 knockdown (42956) results in lifespan 
only marginally longer than pmm2 nulls (HTS: 68 hph; n=63), whereas the weaker ubiquitous 
pmm2 knockdown (107619)allows survival to late larval stages (HTS: 168 hph; n=90) with some 
pupation (mean 192 hph; Fig. 12B). UH1/+ controls pupate at 96 hph, showing ubiquitous 
pmm2 knockdown (107619)exhibits severe developmental delay. Muscle-specific 24B-Gal4 with 
the stronger RNAi42956 produces 100% pupal lethality, whereas weaker 24B>RNAi107619 survives 
with reduced adult lifespan (HTS: 10 days; n=159) compared to control (24B-Gal4/+, HTS: 38 
days; n=79; Fig. 12B). Targeted neural elav-Gal4 with RNAi42956 exhibits similarly reduced adult 
lifespan (HTS: 17 days; n=92), which is conversely extended with weak elav>RNAi107619 (HTS: 65 
days; n=51) compared to control (elav-Gal4/+, HTS: 39 days; n=68; Fig. 12B). This suggests a 
delicate PMM2 balance, with strong neural loss detrimental but moderate neural loss extending 
lifespan. Due to these lethality constraints, hereafter weaker RNAi107619 is used for ubiquitous 
knockdown and stronger RNAi42956 is used for tissue-targeted neural and muscle knockdown.  
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Neuronal PMM2 maintains normal posture and coordinated movement 
Neurological movement symptoms in CDG-Ia patients range from slight gait ataxia to 
severe cerebellar ataxia; most children are unable to walk unassisted, and most adults are 
wheel-chair bound (Barone et al., 2014; Barone et al., 2015; Marquardt and Denecke, 2003; 
Monin et al., 2014). Loss of Drosophila PMM2 results in similarly severe postural and movement 
phenotypes, largely due to nervous system involvement. Targeted neural elav-Gal4 knockdown 
results in a highly penetrant “held-out wings” posture (Fig. 12C), which is associated with 
defects in flight muscle control of wing positioning (Muller et al., 2010; Zaffran et al., 1997). 
Neural pmm2 knockdown adults have severe ataxia, with profound incoordination, inability to 
walk in a directed fashion and complete inability to fly. Weak muscle-specific PMM2 
knockdown does not yield ataxia. However, strong muscle-specific knockdown allows pupae to 
develop fully, but not a single pharate adult properly ecloses. A few animals partially eclose 
before dying, and animals mechanically freed from pupal cases do not move or survive. Based 
on these severe qualitative movement defects, we conducted a range of quantitative analyses 
(Fig. 12D).  
 Larval locomotion requires a CNS pattern generator driving coordinated stimulation of 
segmental nerves to drive neuromuscular junction (NMJ) transmission evoking coordinated 
muscle contraction (Gjorgjieva et al., 2013; Kohsaka et al., 2014; Nichols et al., 2012; 
Sokolowski, 1980). Locomotion was assayed on apple juice agar plates, monitoring movement 
from the barren center to a yeast reward located along the rim (Fig. 12D, left). At 24 hph, 
pmm2 null 1st instar mutants display a significant reduction in coordinated movement, as 
measured in peristaltic waves/second (pmm2FS2, 0.71±0.06 w/s; n=17) compared to genetic 
control (w1118, 1.04±0.02 w/s; n=17; p<0.0001; Fig. 12E). Both lifespan and movement data 
show ubiquitous pmm2 knockdown (42956) phenocopies the pmm2 genetic nulls. Similarly, 3rd 
instar ubiquitous pmm2 knockdown (107619)show a comparable reduction in larval locomotion 
in peristaltic waves/second (0.51±0.04 w/s; n=20) compared to controls (UH1-Gal4/+, 1.06±0.04 
w/s; n=20, p<0.0001; Fig. 12E). Thus, global PMM2 loss dramatically impairs coordinated 
movement needed to maintain viability. 
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Neural-specific PMM2 involvement was next tested in adults, using a range of 
established assays (Nichols et al., 2012). Negative geotaxis assays animals the ability to climb 
vertically (2cm) from the bottom of a vial (Fig. 12D, middle). Neurally-targeted elav-
Gal4>RNAi42956 prevents this simple task, whereas nearly all control animals display the 
necessary coordinated locomotion at 5 seconds (elav-Gal4/+, 90±2.1%, n=50) and 10 seconds 
(elav-Gal4/+, 93±2.4%, n=50; Fig. 12F). Not a single pmm2 RNAi animal performed the task 
(n=40, p<0.0001). A less demanding horizontal locomotion assay measures the time required to 
escape a 4cm diameter circle (Fig. 12D, right). Neurally-targeted elav-Gal4>RNAi42956 results in a 
150-fold delay (302.0±60.02 sec; n=15) compared to controls (elav-Gal4/+, 1.93±0.32 sec; n=15; 
p<0.0001; Fig. 12G). Mutants exit the ring by uncoordinated flailing/kicking, with only a few 
animals crossing the circle in a directed, purposeful manner. These results show a strong PMM2 
role for coordinated movement, similar to CDG-Ia patient symptoms, with a striking PMM2 
impact on neurons. 
 
PMM2 loss suppresses N-glycosylation and enhances glycan turnover 
 To assess N-linked glycoprotein glycosylation levels correlating with movement defects 
in pmm2 null mutants and neurally-targeted RNAi knockdown, we next assayed glycome 
composition. Human CDG-Ia patients display altered glycosylation status, including reduced 
concanavalin A (ConA) binding but increased fucose-decorated glycoproteins (Dijk et al., 2001).   
In Drosophila, at all stages of development and in all tissues, the major N-linked glycoprotein 
constituent glycans include high-mannose and pauci-mannose (>3 mannose residues) classes, 
whereas human glycosylation is typically more branched and complexly decorated (ten Hagen 
et al., 2009; Katoh and Tiemeyer, 2013). Complex hybrid and branched N-glycans are present in 
Drosophila, but at much lower relative abundances (Aoki et al., 2007). Here, Drosophila N-
linked glycans were analyzed by mass spectrometry (MS) throughout the larval body in pmm2 
null mutants and with combined neuronal (elav-Gal4) and muscle (24B-Gal4) pmm2 RNAi, and 
in adult heads only with neurally targeted pmm2 RNAi (Fig. 13).  
 N-linked glycans were released from equal amounts of input pmm2 null (pmm2FS1) 
compared to genetic background control (w1118). Proteins analyzed by MS were dramatically  
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Figure 13: PMM2 loss dramatically alters N-linked glycoprotein glycosylation.  
Full mass spectrometry (MS) spectra for permethylated glycans harvested from (A) age-
matched w1118 genetic control (top) and pmm2FS1 null (bottom) 1st instars, (B) elav-Gal4,24B-
Gal4/+ transgenic control (top) and elav-Gal4,24B-Gal4>RNAi42956 (bottom) 3rd instars, and (C) 
elav-Gal4/+ transgenic control (top) and elav-Gal4>RNAi42956 (bottom) adult heads. Dashed lines 
indicate the relative abundance of Man9GlcNAc2 (m/z=1210.1, doubly-charged) in each control 
for comparison with mutants across genotypes. In all panels, mass peaks at m/z=692.4 and 
899.5 are Hex3 and Hex4 glycans spiked into samples as external calibration standards. The 
cartoon representations of glycan structures are shown in accordance with glycomics 
community conventions (Varki and Sharon, 2009).  
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reduced for all major classes (high-mannose, pauci-mannose and complex; Fig. 13A). For 
example, the relative abundance of Man9GlcNAc2 (m/z=1210.1, doubly-charged), a dominant 
structure in the glycan profile, is down 4-fold in pmm2 null mutants (Fig. 13A; dashed line). All 
other detected N-glycans exhibit comparable reductions, consistent with a global suppression 
of glycoprotein glycosylation. A similar global reduction occurs in 3rd instar larva using paired 
neural and muscle Gal4s to drive pmm2 RNAi (elav,24B>RNAi42956; Fig. 13B).  Interestingly, 
neurally-targeted pmm2 RNAi in the adult head does not produce the same phenotype.  N-
linked glycan quantities are relatively comparable for transgenic control (elav-Gal4/+) and this 
targeted pmm2 knockdown (elav-Gal4>RNAi42956; Figs. 13C). Major complex N-linked glycans 
(e.g. NM3N2F, m/z=1591.0, singly-charged) are not noticeably changed in abundance. However, 
pauci-mannose glycans display clearly increased abundance. For example, the core-fucosylated 
trimannosyl glycan M3N2F (m/z=1345.7, singly-charged) is increased in relative abundance, as is 
non-fucosylated M3N2 (m/z=1172.0, singly charged), with pmm2 knockdown (Figs. 13C).  
Loss of N-linked glycoprotein glycosylation in pmm2FS1 mutants implies decreased 
efficiency in glycosylation initiation by the oligosaccharyltransferase complex (OST) in the 
endoplasmic reticulum, and/or increased ERAD-mediated protein deglycosylation within the 
cytoplasm (Gao et al., 2011). Either mechanism should be reflected in increased abundance of 
free oligosaccharide (FOS), branched oligosaccharides unbound to lipid or protein,, either due 
to endogenous PNGase release or via lipid-linked precursor hydrolysis by the OST (Cline et al., 
2011; Gao et al., 2011). Consistently, FOS abundance is strikingly increased in pmm2FS1 mutants 
(Fig. 14A). FOS abundance is detected as products of PNGase and endo-N-
acetylglucosaminidase digestion (N1, blue asterisks) or glycans possessing two reducing 
terminal GlcNAc residues (N2, red asterisks; Fig. 14A), with total ion mapping chromatograms 
filtered for loss of non-reducing terminal HexNAc residues. Both FOS classes are increased in 
pmm2 nulls compared to control (Fig. 14A). Thus, glycomics and FOS assays show striking 
reduction in mature glycan abundance globally, and altered glycomic repertoire in the nervous 
system with PMM2 loss. To test for cellular requirements, we next moved to the well-
characterized NMJ driving movement.  
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Figure 14: PMM2 loss increases FOS and reduces NMJ N-linked glycoprotein glycosylation.  
A) Free oligosaccharides (FOS) from w1118 genetic control and pmm2FS1 null 1st instar larvae. FOS 
detected as products of sequential PNGase and endo-N-acetylglucosaminidase digestion (N1, 
blue asterisks), or as glycans with 2 reducing terminal GlcNAc residues (N2, red asterisks). Total 
ion mapping chromatograms filtered for loss of non-reducing terminal HexNAc residues to 
show the two FOS classes. B) Representative images of Erythrina cristagalli (ECL, green; left), 
Vicia villosa (VVA, red; middle) and horse radish peroxidase (HRP, green; right) NMJ labeling in 
pmm2 knockdowns (bottom) compared to transgenic controls (top). C) Quantification of 
fluorescent labeling intensity in UH1-Gal4/+ transgenic control vs. UH1-Gal4>RNAi107619. 
Significance: p<0.01 (**), p<0.0001 (****). Sample sizes: n>24 NMJs/12 animals per genotype.   
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PMM2 maintains the normal glycan environment in the NMJ synaptomatrix 
Glycan-binding lectin probes have long been used to chart the cellular carbohydrate 
landscape at both mammalian and Drosophila synapses (Jumbo-Lucioni et al., 2014; Parkinson 
et al., 2013; Schneider et al., 2011). To assay the composition of the heavily-glycosylated larval 
NMJ synaptomatrix, we utilized a panel of lectins, including Erythrina cristagalli (ECL) to label D-
galactose glycans, Vicia villosa (VVA) to label N-acetylgalactosamine glycans, and anti- 
horseradish peroxidase (HRP) to lab alpha1-3-linked fucose moieties (Jumbo-Lucioni et al., 
2014; Kurosaka et al., 1991). Both ECL and VVA reveal strong reductions in ubiquitous pmm2 
knockdown (107619) compared to the UH1-Gal4/+ controls (Fig. 14B). Quantification reveals 
>50% ECL reduction (UH1-Gal4>RNAi107619, 0.43±0.05; UH1-Gal4/+, 1.00±0.08; n=24; p<0.0001) 
and >30% VVA reduction (UH1-Gal4>RNAi107619, 0.69±0.05; UH1-Gal4/+, 1.00±0.05; n=24; 
p<0.0001; Fig. 14C). HRP is reduced by >20% (UH1-Gal4>RNAi107619, 0.79±0.06; UH1-Gal4/+, 
1.00±0.06; n=24; p<0.01; Fig. 14C). Dual neural and muscle knockdown elav-Gal4,24B-Gal4 RNAi 
also exhibits >20% HRP loss (elav-Gal4,24B>RNAi42956, 0.79±0.06; elav-Gal4,24B/+, 1.0±0.04; 
n>26, p<0.008). These results indicate a robustly altered glycan composition within the NMJ 
synaptomatrix, which earlier studies have linked to defects in NMJ structural and functional 
development.     
 
PMM2 restricts NMJ structural growth and synaptic bouton differentiation 
Loss of synaptomatrix glycosylation has been shown to result in elevated structural 
elaboration of the Drosophila NMJ, as evidenced by increased branching and excess synaptic 
boutons (Jumbo-Lucioni et al., 2014; Parkinson et al., 2013). To examine NMJ architecture, we 
characterized wandering 3rd instar muscle 4 NMJs labeled for HRP and Discs Large (DLG), to 
illuminate pre- and postsynaptic compartments, respectively (Fig. 15A). Synaptic branches 
(defined as HRP-positive processes with >2 boutons), boutons (defined as DLG-positive synaptic 
-positive labeling) were all 
quantified (Fig. 15B-D). Cell-specific requirements were tested with neuronal (elav) and muscle 
(24B) targeted Gal4 drivers in comparison to ubiquitous (UH1-Gal4) pmm2 knockdown. In all 
cases, loss of PMM2 results in clear NMJ overelaboration, with more branches and  
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Figure 15:  PMM2 loss results in striking NMJ synaptic structural overgrowth.  
A) Representative wandering 3rd instar muscle 4 NMJ images of ubiquitous (UH1, top), neural 
(elav, second), muscle (24B, third) and double (elav, 24B, bottom) driver controls (left column), 
compared to RNAi-mediated pmm2 knockdown (right). NMJs are co-labeled for presynaptic 
HRP and postsynaptic DLG, merged and shown in black-and-white to best illustrate structure. 
Quantification of NMJ branch number (B), bouton number (C) and terminal area (D) in the 
above 8 genotypes compared to w1118 (9 genotypes total). Significance: p<0.01 (**), p<0.001 
(***), p<0.0001 (****). Sample sizes: n>22 NMJs/12 animals for each genotype.   
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supernumerary type Is/Ib synaptic boutons, with ubiquitous RNAi resulting in the greatest level 
of unrestrained NMJ overgrowth (Fig. 15).  
PMM2 loss increases NMJ branching, due to both pre- and postsynaptic roles (Fig. 15A). 
Ubiquitous pmm2 RNAi increases branch number ~2-fold (UH1-Gal4>RNAi107619, 6.3±0.36 
branches, n=24) compared to controls (w1118, 3.7±0.19, n=88; UH1-Gal4/+, 3.9±0.38 branches, 
n=22; p<0.0001; Fig. 15B). Likewise, neural (elav) and muscle (24B) knockdown more weakly 
increase terminal branch number (elav, 5.7±0.40; 24B, 4.2±0.39; elav,24B, 5.7±0.33 branches) 
compared to  transgenic controls (elav-Gal4/+, 4.0±0.47; 24B-Gal4/+, 3.0±0.24; elav,24B-
Gal4/+, 3.5±0.37 branches; p<0.01, p<0.01 and p<0.0001 respectively; Fig. 15B). Consistently, 
bouton number is elevated >2-fold with ubiquitous PMM2 removal (UH1-Gal4>RNAi107619, 
88±3.9 boutons, n=24) relative to controls (w1118, 32±1.4, n=88; UH1-Gal4/+, 36±2.4 boutons, 
n=22; p<0.0001; Fig. 15C). Bouton number is also elevated with neural and muscle knockdown 
(elav, 61±3.8; 24B, 42±3.0; elav,24B, 56.5±2.9 boutons) compared to controls (elav-Gal4/+, 
39±3.3; 24B-Gal4/+, 30±2.0; elav,24B/+, 31.8±2.7 boutons; p<0.0001, p<0.001 and p<0.0001 
respectively; Fig. 15C). Finally, analyses of synaptic terminal area show increased size with 
ubiquitous, neuronal and co-neural/muscle PMM2 loss (p<0.01, p<0.0001 and p<0.0001, 
respectively), but with no significant change upon muscle-specific PMM2 removal (Fig. 15D). 
Synaptic over-elaboration defects occur across the neuromusculature. Compared to the 
above lateral muscle 4 defects (Fig. 15), ventral muscles 6/7 exhibit comparable NMJ 
phenotypes. For example, the synaptic area in elav-Gal4,24B-Gal4/+ transgenic controls 
2) is dramatically expanded in neural and muscle combined knockdown elav-
Gal4,24B-Gal4<RNAi42956 2), a highly significant (p>0.0001) increase. Early lethal 
pmm2 genetic null mutants also exhibit similarly increased NMJ growth and structural 
elaboration in the 1st instar prior to developmental arrest (Fig. 16). Using the structural 
parameters as above, pmm2 nulls manifest increased synaptic branch number (w1118, 1.6±0.11; 
pmm2FS2, 2.2±0.14 branches; p=0.007; Fig. 16B), more bouton formation (w1118, 5.6±0.21; 
pmm2FS2, 7.0±0.32 boutons; p=0.0006; Fig. 16C) and dramatically increased synaptic area 
(w1118, 1.0±0.07; pmm2FS2, 1.5±0.05 ; p=0.0001; Fig. 16D). Consistently, pmm2 null mutants 
exhibit a loss of synaptic N-linked glycosylation, including >20% decrease in HRP glycan labeling  
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Figure 16:  Early lethal pmm2 null mutants exhibit NMJ overgrowth and loss of N-glycans.  
A) Representative 1st instar muscle 4 NMJ images from genetic background control (w1118, left) 
and pmm2 null mutant (pmm2FS2, right). NMJs are labeled for the presynaptic anti-HRP. 
Quantification of synaptic branch number (B), bouton number (C), synaptic terminal area (D) 
and HRP fluorescence labeling intensity (E). Significance: p<0.05 (*), p<0.01 (**), p<0.001 (***) 
and p<0.0001 (****). Sample sizes: n>30 NMJs/13 animals per genotype.   
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(w1118, 1.0±0.08; pmm2FS2, 0.80±0.04; n>30, p<0.05; Fig. 16E). To determine how NMJ 
overgrowth compares to synaptic function, we next turned to electrophysiological studies.   
 
Coupled pre- and postsynaptic PMM2 function limits NMJ transmission strength 
Glycosylation has been shown to play key roles in NMJ functional differentiation and the 
determination of neurotransmission strength (Dani et al., 2012; Dani et al., 2014; Parkinson et 
al., 2013). The severely impaired coordinated locomotion and alterations in NMJ structure 
similarly suggest PMM2 roles in synaptic function. We tested neurotransmission in the two-
electrode voltage-clamp (TEVC) recording configuration, by stimulating the motor nerve with a 
glass suction electrode and measuring the evoked excitatory junctional current (EJC) from the 
voltage-clamped muscle (Parkinson et al., 2013). To compare EJC transmission properties, 10 
consecutive stimulation recordings were made at 0.2Hz, and then averaged to calculate the 
mean peak transmission amplitude. Cell-specific roles in functional differentiation were tested 
with targeted neuronal (elav) and muscle (24B) Gal4 drivers, alone and in combination, in 
comparison to ubiquitous (UH1-Gal4) pmm2 RNAi knockdown (Fig. 17).  
PMM2 loss dramatically increases neurotransmission strength due to an unusual 
coupled role in both pre- and postsynaptic cells (Fig. 17A). Sample recordings show that all 
transgenic controls and the genetic background control (w1118) have comparable EJC properties, 
and only ubiquitous and combined pre- and postsynaptic PMM2 knockdown strongly and 
equally increase transmission amplitude (Fig. 17A). Ubiquitous RNAi increases peak EJC values 
by ~75% (UH1-Gal4>RNAi107619, 1.73±0.09 (450.2±23.72nA), n=21; w1118, 1.00±0.03 
(253.68±8.26nA), n=44; UH1-Gal4/+, 1.11±0.06 (288.57±14.39nA), n=21; p<0.0001; Fig. 17B). 
Strong PMM2 knockdown in either neuron (elav-Gal4>RNAi42956, 1.03±0.04 (301.8±12.66nA), 
n=16) or muscle (24B-Gal4>RNAi42956, 1.20±0.05 (320.7±13.41nA), n=18) has no significant 
impact on amplitude compared to controls (elav-Gal4/+, 0.99±0.04 (289.9±12.09nA), n=17; 
24B-Gal4/+, 1.20±0.04 (302.4±10.90nA), n=16; Fig. 17B). However, coincident pmm2 RNAi 
driven in both the presynaptic neuron and postsynaptic muscle again shows significantly 
(p<0.0001) increased EJCs (elav-Gal4,24B-Gal4>RNAi42956, 1.91±0.05 (397.61±11.58nA), n=23)  
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Figure 17: Coupled pre- and postsynaptic PMM2 removal increases neurotransmission.  
A) Representative two-electrode voltage-clamp (TEVC) recordings of nerve-stimulation evoked 
excitatory junctional currents (EJCs) from wandering 3rd instar muscle 6. Superimposed traces 
are shown in response to nerve stimulation at 1.0mM Ca2+ comparing UH1-Gal4>RNAi107619, 
elav-Gal4>RNAi42956, 24B-Gal4>RNAi42956 and elav-Gal4, 24B-Gal4>RNAi42956 to w1118 and Gal4 
diver alone controls. Quantification of peak EJC amplitude normalized to w1118 (B) and 
neurotransmission quantal content (C) Significance: p<0.0001 (****). Sample sizes: n>16 
NMJs/8 animals per genotype.  
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compared to the dual driver control alone (elav-Gal4,24B-Gal4/+, 1.11±0.07 (231.0±14.56nA), 
n=23; Fig. 17B). We next recorded miniature evoked junction currents (mEJC) in neural and 
muscle combined knockdown elav-Gal4,24B-Gal4>RNAi42956 but did not detect any significant 
change in either frequency (elav-Gal4,24B-Gal4/+, 1.80±0.11 Hz; elav-Gal4,24B-Gal4/42956, 
1.93±0.14 Hz; n.s. n=20) or amplitude (elav-Gal4,24B-Gal4/+, 0.66±0.02 nA; elav-Gal4,24B-
Gal4/42956, 0.61±0.03 nA; n.s. n=20)  compared with control but quantal content (QC) was 
elevated >80% (elav-Gal4,24B-Gal4/+, 362.0±13.9 QC; elav-Gal4,24B-Gal4/42956, 677.6±29.9 
QC; Fig. 17C)). Thus, PMM2 specifically regulates evoked quantal content (Fig. 17C). These 
results indicate the NMJ functional defect is not cell autonomous, as either pre- or postsynaptic 
PMM2 is sufficient to properly regulate neurotransmission strength. We therefore began to 
test non-cell autonomous molecular mechanisms that could underlie the PMM2 function. 
  
PMM2 positively regulates the synaptic extracellular matrix proteinase pathway  
Extracellular mechanisms in the highly-glycosylated NMJ synaptomatrix provide an 
obvious answer to PMM2 non-cell autonomous phenotype. We were first guided to consider 
extracellular matrix metalloproteinase (MMP) pathways owing to common tracheal break and 
melanization mutant phenotypes (Glasheen et al., 2010; Page-McCaw et al., 2007; Zhang and 
Ward, 2009) shared with PMM2 loss-of-function (data not shown). Subsequently, recent work 
has shown that mmp mutants exhibit both NMJ structural and functional phenotypes strikingly 
similar to PMM2 loss-of-function (Dear et al., 2016). Therefore, we examined the matrix 
metalloproteome at the NMJ, which includes secreted MMP1, GPI-anchored MMP2 and their 
shared secreted tissue inhibitor of MMP (TIMP) (Dear et al., 2016; Kessenbrock et al., 2010; 
Page-McCaw et al., 2007). We hypothesized that PMM2-dependent glycan modification of 
these extracellular proteins, and/or their synaptic substrates, could provide a mechanism 
regulating NMJ structure and function. Consistent with this hypothesis, utilizing PNGaseF and 
EndoH to remove N-linked glycosylation (Song et al., 2011) reveals a clear reduction in MMP 
size (Fig. 18A), showing a high level of glycosylation (Glasheen et al., 2009; Jia et al., 2014). This 
change is much greater for membrane-anchored MMP2, in which all major isoforms show  
 
112 
 
 
Figure 18  
113 
 
Figure 18: Loss of PMM2 down-regulates the synaptic matrix proteinase pathway. 
A) Representative Western blots for MMP1 (left) and MMP2 (right); 1) with/without PNGaseF 
and EndoH enzymatic treatment to remove glycosylation, and 2) in UH1-Gal4/+ transgenic 
control and UH>RNAi107619 PMM2 knockdown conditions. The asterisks denote shifted bands. B) 
Representative NMJ images for anti-MMP1 (green, left), anti-MMP2 (green, center) and anti-
TIMP (red, right) in UH1-Gal4/+ controls and UH1-Gal4>RNAi107619. C) Normalized quantification 
of fluorescent intensities for all three proteins. Significance: p<0.001 (***), p<0.0001 (****) and 
not significant (n.s.). Sample sizes: n>20 NMJs/12 animals per genotype. 
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glycosylation-dependent shifts in size (Fig. 18A, asterisks), compared to secreted MMP1, in 
which only one minor isoform displays glycosylation. We next tested for non-glycosylated MMP 
forms in mutants using UH1-Gal4 driven pmm2 knockdown (Fig. 18A). Loss of PMM2 results in 
multiple shifted (non-glycosylated) MMP bands compared to controls. Again, the effect is much 
greater for MMP2, with multiple bands showing a PMM2-dependent loss of glycosylation (Fig. 
18A, asterisks). Consistently, NMJ labeling in pmm2 RNAi compared to controls shows the 
synaptic matrix metalloproteome is compromised, again particularly for MMP2 (Fig. 18B). 
PMM2 ubiquitous knockdown results in >50% reduction in MMP2 levels (UH1-Gal4>RNAi107619, 
0.44±0.04, n=32) normalized to control (UH1-Gal4/+, 1.00±0.08, n=32; p<0.0001; Fig. 18C). In 
contrast, there is no significant change in MMP1 expression, although there is a slight 
decreasing trend (UH1-Gal4>RNAi107619, 0.87± 0.07, n=20; UH1-Gal4/+, 1.00±0.07, n=24; Fig. 
18B.C). TIMP is also reduced with PMM2 loss (UH1-Gal4>RNAi107619, 0.60±0.07, n=24) compared 
to control (UH1-Gal4/+, 1.00±0.08, n=24; p<0.001; Fig. 18B,C). These results show synaptic 
MMP2 is strongly reduced by PMM2 removal, with a reduction also in synaptic TIMP levels. 
Given the importance of the synaptic metalloproteome in shaping Wnt trans-synaptic signaling 
(Dear et al., 2016), we next tested predicted PMM2 involvement.   
 
PMM2 positively regulates the Wnt Wingless trans-synaptic signaling pathway   
MMPs play an important role in Wnt Wingless (Wg) intercellular signaling by directly 
regulating the HSPG Dally-like protein (Dlp) Wg co-receptor (Wang and Page-McCaw, 2014). 
Importantly, the same Wg/Dlp signaling pathway is a critical driver of structural and functional 
development at the Drosophila NMJ (Ataman et al., 2006, 2008; Kerr et al., 2014; Mathew et 
al., 2005) and is known to be modulated by glycan mechanisms (Dani et al., 2012; Jumbo-
Lucioni et al., 2014; Parkinson et al., 2013). Wg binds the Frizzled-2 (Fz2) receptor, which is 
internalized and the C-terminus proteolytically cleaved (Fz2C) for transport via the Fz2C nuclear 
import (FNI) pathway (Ataman et al., 2006; Mathew et al., 2005) to modulate NMJ 
structure/function (Speese et al. 2012). Based on this extensive work, we hypothesized that 
PMM2 regulates MMP2-dependent Wg signaling to regulate NMJ structure and function 
underlying coordinated movement and maintained viability.  
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Figure 19: Loss of PMM2 down-regulates the trans-synaptic Wnt signaling pathway.  
A) Representative NMJ images for anti-Wg (red, left), anti-Dlp (green, middle) and anti-Fz2C 
(red, right) in UH1-Gal4/+ controls (top) and UH1-Gal4>RNAi107619 (bottom). Left: Arrow 
indicates high Wg-expressing bouton, and arrowheads show low Wg-expressing boutons in 
control NMJ. Right: The arrows indicate two postsynaptic nuclei in control and mutant muscle. 
B) Normalized quantification of Wg, Dlp and Fz2C fluorescent labeling intensities. Significance: 
p<0.01 (**) and p<0.001 (***).  Sample sizes: n>24 NMJs or nuclei/12 animals per genotype.   
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All 3 components of the signaling pathway show clear down-regulation with PMM2 loss 
(Fig. 19). Qualitative comparison of Wg ligand and Dlp co-receptor at the NMJ, and Fz2C 
cleavage/import into the postsynaptic muscle nuclei, all show reduction of pathway 
components and impairment of downstream signaling (Fig. 19A). Quantification of the 
extracellular Wg levels shows a ~50% reduction with PMM2 ubiquitous knockdown (UH1-
Gal4>RNAi107619, 0.55±0.05, n=32) normalized to control (UH1-Gal4/+ 1.00±0.11, n=30; p<0.001; 
Fig. 19B, left). Wg co-receptor Dlp is also reduced (UH1-Gal4>RNAi107619, 0.72±0.07, n=24) 
compared to control (UH1-Gal4/+, 1.00± 0.06, n=24, p<0.01; Fig. 19B, middle). Finally, 
consequent Fz2C import into the muscle nucleus via the FNI pathway to mediate downstream 
signaling is significantly impaired with PMM2 ubiquitous knockdown (UH1-Gal4>RNAi107619, 
0.78±0.05, n=24) compared to control (UH1-Gal4/+, 1.00±0.04, n=24), showing a significant 
decrease in trans-synaptic signaling (p<0.01; Fig 19B). These results agree well with the recent 
report of strongly reduced Wnt signaling in the Xenopus PMM2-CDG model (Himmelreich et al., 
2015). We conclude that neurological impairments in the Drosophila PMM2-CDG model 
similarly map to impaired Wnt signaling, to misregulate NMJ synaptogenesis underlying 
coordinated movement.  
 
Discussion  
 We set forth to establish a Drosophila CDG-Ia (aka PMM2-CDG) genetic model through 
manipulation of the causative phosphomannomutase type 2 (PMM2) gene (Freeze et al., 2014). 
Using CRISPR-generated pmm2 null mutants and transgenic RNAi, we found PMM2 levels 
correlated to coordinated movement abilities and lifespan (Fig. 12), as in CDG-Ia patients 
(Cylwik et al., 2013; Jaeken, 2013; Lonlay et al., 2001). Human patients with identical pmm2 
mutations present with a wide spectrum of movement defects (Marquardt and Denecke, 2003; 
Schneider et al., 2011), attributed to genetic and/or environmental factors readily controlled in 
Drosophila. With tissue-specific drivers, we found a neural PMM2 impairment for coordinated 
movement (Fig. 12). Interestingly, weak neural knockdown of pmm2 resulted in increased 
lifespan. Similarly, moderate impairments of oxidative stress and dietary restriction pathways 
have also been reported to extend lifespan (Mair et al., 2005; Min and Tartar, 2006; Ristow and 
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Schmeiser, 2011). Like PMM2, severe impairments of these pathways result in reduced lifespan 
and early death, but more modest impairments extend lifespan via changes in metabolic rate, 
developmental conditioning and/or defense mechanisms. Null pmm2 mutants display severe 
attenuation of glycoprotein glycosylation (Fig. 13), with reduced N-linked glycosylation diversity 
(Aoki et al., 2007). Similar global N-glycan losses occur with strong pmm2 RNAi throughout the 
larval neuromusculature, but not with weaker neural-targeted pmm2 RNAi in the adult head 
(Fig. 13). Lipid-linked oligosaccharides (LLO) used for protein attachment by 
oligosaccharyltransferase (OST) activity are regulated at many levels (Gao et al., 2011). PMM2 
loss should reduce LLO levels by inhibiting mannose-1-phosphate production and elevating the 
mannose-6-phosphate pool acting as a signal mediating LLO destruction, thereby increasing 
free oligosaccharides (FOS; Fig. 14A; Gao et al., 2011). However, the increase in pauci-mannose 
structures with adult neuronal pmm2 knockdown differentially alters glycan maturation. The 
mannose-6-phosphate increase may change the mannose phosphoisomerase (MPI) 
equilibrium, leading to interconversion of mannose-6-phosphate to fructose-6-phosphate to 
siphon LLO-toxic mannose-6-phosphate and mitigate LLO elimination.  
Null pmm2 mutants display elevated FOS levels (Fig. 14A). Increased phosphorylated 
FOS levels, predicted to be cleaved from LLO intermediates, likewise occur in CDG-Ia patient 
cells (Vleugels et al., 2011). Similarly, the zebrafish morpholino model shows increased FOS 
levels, with phenotype rescue via MPI co-reduction, suggesting causative mannose-6-
phosphate elevation (Cline et al., 2012). Viable human CDG-Ia patients are typically 
heterozygous for pmm2 mutations, resulting in partial loss of PMM2 (Matthijs et al., 1998; 
Monin et al., 2014). In Drosophila, partial loss-of-function from neuron-targeted RNAi results in 
surprising resistance to glycosylation changes (Fig. 13C). Pauci-mannose glycans are increased, 
but high mannose and complex glycans unchanged. PMM2 regulates GDP-mannose availability 
for glycan production, but following glycosylation by OST further processing should be GDP-
mannose independent (Cylwik et al., 2013). The increased pauci-mannose glycans resulting 
from PMM2 partial loss suggests GDP-mannose levels influence glycan processing beyond the 
role as synthetic donors for mannosylation. Pauci-mannose glycan production is driven by the 
balance between Golgi exomannosidases, GlcNAc-Transferase 1 and a hexosaminidase 
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removing GlcNAc from nascent complex glycans (Stanley et al., 2009). Precursor abundances, 
including donor and acceptor, influence expression and activity of glycan-processing enzymes. 
Reduced GDP-mannose likely skews the balance of enzyme activities that trim high-mannose to 
pauci-mannose, before they increase in complexity. Impacts on glycosylation independent of 
GDP-mannose is also evident in reduced NMJ lectin labeling with PMM2 loss (Fig. 14B). 
Importantly, both ECL and VVA bind mannose-free structures, most likely on O-linked 
glycoprotein backbones.   
The nervous system is tightly regulated by glycans at multiple levels of development and 
function (Koles et al., 2007; Scott and Panin, 2014a,b; Seppo and Tiemeyer, 2000). NMJ 
architectural overelaboration and functional strengthening has been identified in many glycan 
mutants in our systematic genetic screens, including sulf1, mgat1, galt and pgant (Dani et al., 
2012; Dani et al., 2014; Jumbo-Lucioni, 2014; Parkinson et al, 2013). Consistently, PMM2 loss 
shows striking NMJ overelaboration (Fig. 15), supporting the conclusion that glycans primarily 
inhibit synaptic morphogenesis. Null pmm2 mutants already exhibit strong synaptic 
architecture defects within a day after hatching (Fig. 16), showing that PMM2-dependent 
glycan mechanisms brake the earliest stages of synaptic growth and differentiation. 
Glycosylation mechanisms also have key roles modulating neurotransmission (Koles et al., 
2007; Scott and Panin, 2014a,b), and PMM2 loss strongly increases NMJ function (Fig. 17). 
There is no effect on spontaneous synaptic vesicle release or postsynaptic amplitude, indicating 
a specific PMM2 role in limiting stimulus evoked quantal content. Interestingly, neural- and 
muscle-targeted PMM2 knockdown have no effect on transmission, however combined neural 
and muscle knockdown fully replicates the ubiquitous PMM2 loss phenotype (Fig. 17), 
indicating that the elevated transmission needs concomitant PMM2 removal both pre- and 
postsynaptically. One explanation is that semi-synaptic glycosylation may be sufficient to 
normalize transmission: loss of glycosylation from one side may be compensated for by the 
other side, as synapse transmission is highly regulated by both pre- and postsynaptic cells (Dani 
and Broadie, 2012). Another idea is that glycosylation could be provided by extracellular 
components from either synaptic partner cell. 
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The non-cell-autonomous defect occurring with PMM2 loss prompted us to investigate 
extracellular signaling mechanisms, which are tightly regulated by glycosylation at the NMJ 
(Dani et al. 2012; Dani et al., 2014; Parkinson et al., 2013; Jumbo-Lucioni et al., 2014; Rushton 
et al., 2012). In particular, matrix metalloproteinases (MMPs) play critical roles shaping synapse 
structure and function (Dear et al., 2016; Kessenbrock et al., 2010; Page-McCaw et al., 2007; 
Sternlicht and Werb, 2001). PMM2 loss could impair MMP glycosylation or ability to cleave 
improperly glycosylated substrates (Godenschwege et al., 2000; Llano et al., 2000; Llano et al., 
2002; Pohar et al., 1999). PNGaseF and EndoH treatment to remove N-linked glycans shows 
MMP2 isoforms are highly glycosylated, whereas only a tiny subset of MMP1 isoforms are 
glycosylated (Fig. 18A). GPI-anchored MMP2 also requires GDP-mannose, although GPI anchors 
require fewer donor mannose than N-linked glycans (Morena-Bario et al., 2013). Importantly, 
pmm2 RNAi similarly removes glycosylation from multiple MMP2 isoforms, with only a minor 
change to MMP1 (Fig. 18A). As predicted by PMM2-dependent glycosylation changes, MMP2 is 
strongly reduced at the NMJ synapse with pmm2 RNAi, whereas MMP1 is not significantly 
altered (Fig. 18B,C). The TIMP regulator is also reduced in abundance with removal of PMM2, 
which would be predicted to help alleviate consequences of MMP2 loss, perhaps as a 
compensation mechanism (Dear et al., 2016). Importantly, recent work from our lab has shown 
that MMPs play critical roles regulating NMJ structural and functional synaptogenesis via 
control of heparan sulfate proteoglycan (HSPG) receptors that modulate Wnt trans-synaptic 
signaling (Dear et al., 2016).  
 Recent work utilizing PMM2 morpholino knockdown in Xenopus revealed altered 
glycosylation of Wingless-type MMTV integration site family growth factor (Wnt) and reduction 
of Wnt signaling (Himmelreich et al., 2015). Similarly, we find that pmm2 RNAi knockdown in 
Drosophila suppressing Wnt Wingless (Wg) signaling at the developing NMJ synapse (Fig. 19). 
With PMM2 loss, synaptic levels of Wg ligand and its HSPG co-receptor Dally-like Protein (Dlp) 
are both strongly reduced, and downstream signaling through the Frizzled Nuclear Import (FNI; 
Speese et al., 2012) pathway is consistently down-regulated (Fig. 19). These defects have been 
previously associated with the loss of synaptic MMP2, which acts via Dlp to regulate Wg trans-
synaptic signaling to modulate both structural and functional NMJ development in the same 
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direction (Dear et al., 2016). However, we have shown that PMM2 loss has myriad 
consequences on N-linked glycoprotein glycosylation, and therefore quite likely impacts NMJ 
synaptogenesis at multiple levels. Indeed, specifically targeted reduction in Wg signaling alone 
has previously been associated with decreased NMJ structural development and reduced 
function (Ataman et al., 2008; Kerr et al., 2014; Packard et al., 2002), which differs from the Wg 
attenuation associated with PMM2 loss. Therefore, PMM2 roles at the NMJ synapse likely 
reflect roles in multiple intersecting pathways that jointly control growth, structural 
differentiation and neurotransmission strength. Our future work will aim at deciphering other 
PMM2-dependent glycoprotein contributions, which combinatorially result in the structural and 
functional NMJ defects characterizing this CDG-Ia disease state model. 
 We hope this new Drosophila model will prove instrumental for tackling the disease, 
and related CDGs, especially in regard to neurological symptoms (Grunewald, 2009; Jaeken, 
2010). One avenue will be to dissect roles played by glycan precursors and mannose-6-
phosphate buildup, by examining genetic interactions shifting the relative abundance of 
alternatively processed glycans and to alleviate increased FOS levels. For example, using genetic 
MPI reduction or pharmaceutical MPI inhibitors in the benzoisothiazolone series (Sharma et al., 
2011). One such agent, MLS0315771, has been shown to favor mannose-1-phosphate 
production in CDG-Ia patient fibroblasts and zebrafish embryos. Pharmacological tests in 
Drosophila could include assays to prolong lifespan, improve coordinated movement and 
prevent NMJ structural and functional defects. The current standard of care for CDG-Ia patients 
is simply symptomatic treatment and disease management (Grunewald, 2009; Jaeken, 2013). 
The mouse model suggests beneficial dietary intervention, common for other metabolic 
disorders like Classic Galactosemia (Jumbo-Lucioni et al., 2014). However, mannose treatment 
has not been effective in restoring N-linked glycoprotein glycosylation levels in CDG-Ia patients 
(Thiel and Korner, 2013). Drug avenues to increase PMM2-dependent glycosylation are 
hypothesized, but there are no studies (Thiel and Korner, 2013). We expect the relatively high 
speed of Drosophila disease model studies utilizing the powerful Drosophila genetic toolkit will 
open up new avenues for disease intervention. We propose here that targeting the matrix 
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metalloproteome and Wnt signaling pathways offers potential new candidates to consider in 
developing future CDG-Ia treatments. 
 
Materials and Methods 
Drosophila Genetics  
Drosophila stocks were grown on standard cornmeal/agar/molasses food in a 12 hour light:dark 
cycle at 25C. Mutants were generated with CRISPR/Cas9 (Gratz et al., 2013). Briefly, chiRNA 
targeting 5’CATTGAAGCGTGATGAAATC and 3’AGGATACGCAACGATTCTC sequences of pmm2 
were incorporated into a pU6-BbsI-chiRNA plasmid (Addgene #45946). F1 progeny from w1118 
vas-Cas9 males (BDSC# 51324) crossed to w1118 Lig4 females (BDSC# 28877) were injected with 
both targeting plasmids (BestGene Inc., Chino Hills, CA). Injected animals were then crossed to 
a double balanced (TM3Sb/TM6Tb) mate. F1 males were then crossed to deficiency/balancer 
females (w1118; Df(3L)BSC380/TM6C, Sb1cu1 (BSCD #24404)) to identify lethal pmm2 mutations. 
F1 males were recollected and mated with double balanced females to produce the pmm2 
mutant stocks. Mutant backcrossing and sequencing were performed with standard Drosophila 
genetic and PCR techniques. The w1118 background stock was used as the control. RNAi studies 
were performed with neuronal-specific elav-Gal4, muscle-specific 24B-Gal4 and ubiquitous 
UH1-Gal4 transgenic drivers (Brand and Perrimon, 1993; Lin and Goodman, 1994; Rohrbough et 
al., 2007). Two pmm2 UAS-RNAi lines, v107691 (Vienna Drosophila RNAi Center) and 
BDSC42956 (Bloomington Drosophila Stock Center) were used, with Gal4 drivers alone as 
transgenic controls.  
 
PCR Methods 
For reverse transcription quantitative PCR (RT-qPCR), total RNA was extracted using a Zymo 
Research Direct-zol RNA Miniprep Plus Kit with TRI reagent (R2070) with on column DNase 
treatment. The Superscript VILO cDNA synthesis kit (11754-050) was used for cDNA synthesis. 
RT-qPCR was run on a Biorad CFX96 with equal amounts of cDNA (2ng for each trial). For 
expression quantification, the Pfaffl Method was used with standards of known transcript 
number to quantify absolute cDNA number for target and reference genes. For the reference, 
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ribosomal protein L32 (CG7939) levels were used for normalization of absolute cDNA quantity 
((target/reference)*100). The following primers were used for target and reference: pmm2 
forward AGGCTCGGATCTGGAGAAGA, pmm2 reverse AATGTCGTACTCGGCGAACA; L32 forward 
CGGTTACGGATCGAACAAGC, L32 reverse CTTGCGCTTCTTGGAGGAGA. Samples and standards 
were run with gene specific primers in duplicate trials.   
 
Behavioral Assays  
Egg lays were collected overnight on apple juice agar plates. Plates were then cleared of larvae, 
and newly-hatched larvae collected after 1 hour (t=0). Larval lifespan analyses involved daily 
counts. Adult lifespan analyses required two separate methods. For strong neural elav-
Gal4>RNAi pmm2 knockdown and elav-Gal4/+ controls, adults were collected at eclosion and 
maintained in laying pots with filter paper covering apple juice plates with yeast. For all other 
lifespan assays, adults were maintained in normal fly tubes on cornmeal/agar/molasses food. 
Adult survival was measured 3 times/week, with animals transferred to fresh plates or tubes. 
The comparative quantification of survival is reported as the time to which 50% of the animals 
remain viable (half-time survival, HTS). Adult and larval locomotion were assayed as previously 
described (Nichols et al., 2012; Sokolowski, 1980). Briefly, larvae were tested on apple juice 
agar plates with yeast paste spread around edges as an attractant. Individual larvae were 
placed in the middle of a plate and time-lapse recorded under a dissection microscope with a 
Cannon Rebel DSLR camera (Melville, NY). Locomotion was assayed as peristaltic waves per 
second (Gjorgjieva et al., 2013). Adult motility was assayed by negative geotaxis and a ring 
locomotion assay. For geotaxis, adults were place in empty fly vials for 15 mins to acclimate, 
and then tubes were sharply tapped to put animals at the bottom (Nichols et al., 2012). 
Movement was recorded with a Canon Rebel DSLR camera and the percentage of animals to 
climb above 2cm measured at timed intervals. To assay horizontal locomotion, a 4cm circle was 
drawn in a large dish, and flies with amputated wings were placed in the middle of the circle. 
Movement was recorded with a Canon Rebel DSLR camera and the time required to traverse 
the circle measured.  
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Glycomic Analyses  
Glycoproteins and free oligosaccharides (FOS) were prepared from staged collections of pmm2 
null 1st instars or elav-Gal4>RNAi42956 adult heads by homogenization in aqueous/organic 
solvents and subsequent protein precipitation as described previously (Aoki et al., 2007). 
Briefly, the aqueous/organic homogenate was centrifuged with glycoproteins recovered in the 
pellet and FOS from the supernatant (Katoh et al., 2013). Precipitated proteins were washed 
with cold acetone and dried under a stream of nitrogen to produce samples stored desiccated 
at -20oC.  Protein content was determined by BCA assay of resolubilized material (Pierce). N-
linked glycoprotein glycans were prepared from 1 mg aliquots by digestion with 
trypsin/chymotrypsin, followed by enzymatic release of glycans with PNGaseF (Aoki et al., 
2007). FOS were separated by passage over a Sep-pak C18 cartridge column (Katoh et al., 2013).  
N-linked glycans and FOS were permethylated and analyzed by mass spectrometry (MS) using 
nanospray ionization coupled to linear iontrap and orbital Fourier transform mass analyzers 
(Discover NSI-LTQ/OrbitrapFT, Thermo-Fisher Scientific). MS spectra were collected over the 
range m/z=200-2000 and MS/MS fragmentation by collision-induced dissociation (CID; 30-40% 
normalized collision energy) was acquired over the same m/z range using the total ion mapping 
function of the XCalibur instrument software (version 2.0). Annotated glycans were validated by 
exact mass in full MS and by manual inspection of MS/MS spectra at each of the detected m/z 
values. 
 
Immunocytochemistry Imaging  
Immunocytochemistry studies were performed as described previously (Parkinson et al., 2013). 
Briefly, all animals were dissected, fixed and labeled identically in the same dish. Wandering 3rd 
or 1st instars were dissected in physiological saline containing 128mM NaCl, 2mM KCl, 4mM 
MgCl2, 0.25mM CaCl2, 70mM sucrose, 5mM trehalose and 5mM HEPES (pH 7.1). Preparations 
were fixed in 4% paraformaldehyde for 10 mins at room temperature (RT) in phosphate 
buffered saline (PBS). Preparations were then either processed with detergent (PBS + 1% 
bovine serum albumin (BSA) + 0.2% Triton X-100) for intracellular labeling, or detergent-free 
(PBS with 1% BSA) for extracellular studies. Primary antibodies included: rabbit anti-horseradish 
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peroxidase (HRP, 1:200; Sigma, St. Louis, MO); conjugated CY2, CY3 or CY5-HRP (1:250, Jackson 
Labs, West Grove, PA); mouse anti-Wingless (Wg, 1:2; Developmental Studies Hybridoma Bank 
(DSHB), University of Iowa, Iowa City, Iowa); mouse anti-Discs Large (DLG, 1:200; DSHB). Lectins 
included: Vicia villosa agglutinin (VVA-Tritc, 1:200, E.Y. Laboratories, San Mateo, CA) and 
Erythrina cristagalli lectin (ECL-biotin, 1:250, Vector Labs). Secondary Alexa fluorophore 
antibodies (Invitrogen, Grand Island, NY) included: goat anti-mouse 488 and 568 (1:250), goat 
anti-rabbit 488 and 568 (1:250), and streptavidin 488 and 594 (1:250). Primary antibodies and 
lectins were incubated at 4°C overnight; secondary antibodies were incubated at RT for 2 hours. 
Samples were mounted in Fluoromount-G (Electron Microscopy Sciences, Hatfield, PA). All 
preparations were imaged using identical parameters. Z-stacks were taken with a Zeiss LSM510 
META laser-scanning confocal using a 63X Plan Apo oil immersion objective. Optical sections 
were imaged starting above and ending below the NMJ or muscle nuclei to encompass their 
entirety. Stacks were projected on the Z-axis for maximum intensity, with NMJ or nuclei signals 
highlighted and average intensity quantified using ImageJ (Abramoff et al., 2001). 
 
Western Blot analyses  
Tissues were homogenized in buffer (1% SDS, 50mM Tris-HCl, 150mM NaCl) with protease 
inhibitors, heated (70°C, 10 mins) and centrifuged (16,100xg, 10 mins). Supernatant was split 
into two tubes (+/- enzyme) and glycosidase treatment done following manufacturer 
instructions (New England Biolabs (NEB), Ipswich, MA). Briefly, samples in denaturing buffer 
(NEB) were heated (10 mins, at 95°C) then cooled to RT. Denatured samples were treated with 
or without (buffer alone) Endoglycosidase-H (NEB) and PNGase-F (NEB) at 1 microliter enzyme/ 
20 microgram protein in 1X G5 buffer (NEB) overnight at 37°C. Samples were assayed with 
Western blot SDS-PAGE using 10% Bis-Tris gels and Western blot analysis. Membranes were 
blocked in 2% milk in tris-buffered saline (TBS) for 1 hour at RT. Mmp antibodies (1:1500) were 
incubated overnight 4°C, then washed for 5 mins (x6) in TBS + 0.1% Tween-20 (TBST). Goat 
secondaries (1:10,000; Rockland, Limerick, PA) were incubated for 1 hour RT. Blots washed for 
5 mins (x6) in TBS-T were imaged using an Odyssey Infrared Imaging System. 
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Electrophysiology  
Excitatory junctional current (EJC) recordings made using two-electrode voltage-clamp (TEVC) 
were done as previously reported (Parkinson et al., 2013). Briefly, wandering 3rd instars were 
glued with 3M Vetbond adhesive (World Precision Instruments, Sarasota, FL) to sylgard-coated 
glass coverslips, cut longitudinally along the dorsal midline, internal organs removed and sides 
affixed down for neuromusculature access. Peripheral nerves were cut at the ventral nerve 
cord. Recordings were done at 18°C in saline consisting of 128mM NaCl, 2mM KCl, 4mM MgCl2, 
1mM CaCl2, 70mM sucrose, 5mM trehalose and 5mM HEPES (pH 7.1), imaged using a Zeiss 
Axioskop microscope with 40X immersion objective. A fire-polished glass suction electrode was 
used for evoked nerve stimulation with 0.5 millisecond supratheshold stimuli at 0.2Hz from a 
Grass S88 stimulator (Rohrbough et al., 2007). Muscle 6 in abdominal segments 2/3 was 
impaled with two microelectrodes of 10-15 MΩ resistance filled with 3M KCl, and clamped (-60 
mV) using an Axoclamp-2B amplifier (Molecular Devices, Sunnyvale, CA). EJC records were 
filtered at 2kHz. To quantify EJC amplitudes, 10 consecutive traces were averaged. Spontaneous 
miniature EJC (mEJC) records were made in 2-minute sessions and filtered at 200Hz with a low-
pass Gaussian filter prior to quantification. Clampex software was used for all data acquisition, 
and Clampfit software for all data analyses (Molecular Devices, Sunnyvale, CA).  
Statistics  
All statistical analyses were performed using GraphPad InStat3 software (La Jolla, CA). Student’s 
T-tests were used for pairwise comparisons, and ANOVA with appropriate post-hoc testing was 
used for all data sets of 3 or more comparisons. Nonparametric methods were used for data 
sets lacking normal distribution. Fisher’s exact tests were used to analyze contingency tables for 
adult behavioral data. Data are shown as mean±SEM in all figures, with significance presented 
as p≤0.05 (*), p≤0.01 (**), p≤0.001 (***) and p≤0.0001 (****). 
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CHAPTER IV 
 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
This work was initiated to comprehensively test the role of N-linked glycosylation in 
synaptic mechanisms, using the Drosophila glutamatergic NMJ as a genetic model. The 
anticipation was that the loss of glycosylation would result in catastrophic failure of 
synaptogenesis and/or neurotransmission, so it was surprising to find much more subtle 
requirements. Before this work, relatively little study had been done on glycosylation enzymes 
in the Drosophila model (Geisler et al., 2012; Katz et al., 1988; Whitlock, 1993), other than the 
identification of predicted glycosylation sites on proteins and a few examples of lost glycan 
modifications causing proteins to not fold properly, fail to form a complex or lack function 
(Koles et al., 2007). Parallel glycosylation studies at the Drosophila NMJ conducted in the 
Broadie Lab in the same time-frame as this thesis (Dani et al., 2012, 2014; Jumbo-Lucioni et al., 
2014) revealed increased synaptic structural and functional development in the absence of 
proper modification, validating similar outcomes with Mgat1 and PMM2 genetic manipulations. 
Together, these studies have revealed key glycosylation roles in the extracellular synaptomatrix 
that modulate intercellular signaling to inhibit synaptic development and neurotransmission 
function (Dani et al., 2012, 2014; Jumbo-Lucioni et al., 2014; Parkinson et al., 2013). With this 
new hypothesis, the focus has become understanding the intersection between extracellular 
glycosylation and trans-synaptic signaling pathways driving synaptogenesis.  
 
Mgat1 Conclusions  
The goal here has been to understand how loss of higher order N-glycosylation would 
affect synaptic development and function by utilizing mgat1 null mutants unable to produce all 
hybrid and complex N-glycans (Sarkar et al., 2006; Schachter and Boulianne, 2011). The critical 
role of these species at multiple levels of nervous system development and function predicted a 
profound impact on synaptic mechanisms (Koles et al., 2007; Scott and Panin, 2014; Seppo and 
140 
 
Tiemeyer, 2000). Surprisingly, therefore, mgat1 null mutants showed not a failure of 
synaptogenesis but rather accelerated synaptic growth, overelaborated architecture and 
increased neurotransmission strength at the Drosophila NMJ (Chapter 2). This result was 
validated by a transgenic RNAi screen that identified a general trend for structural 
overelaboration and increased neurotransmission with the knockdown of most glycosylation 
pathways (Dani et al., 2012). This result was further substantiated by mutant studies on 
multiple glycosylation enzyme genes, including sulf1, galt and pgant (Dani et al., 2012; Dani et 
al., 2014; Jumbo-Lucioni, 2014), which all showed the same accelerated synapse development 
and elevated synaptic function. To probe specific glycan changes in mgat1 null NMJs, 
synaptomatrix composition was probed for bi-fucosylated N-glycans with anti-HRP (Desai et al., 
1994; Katz et al., 1988; Kurosaka et al., 1991) and terminal GalNAc glycans with Vicia villosa 
(VVA) lectin (Haines et al., 2007). Both glycan classes were grossly reduced at the mutant NMJ 
(Chapter 2). This was a counter-intuitive result since key synaptic proteins with HRP (Fasciclins, 
Neurotactin and Neuroglian) and VVA (Dystroglycan) glycan modification are generally required 
to stabilize the synapse (Desai et al., 1994; Haines et al., 2007; Nakamura et al., 2010; 
Paschinger et al., 2009). It therefore appears that N-glycosylation of these proteins must serve 
to inhibit their function, which is elevated in the mgat1 mutant condition. 
Trans-synaptic signaling requires passage through, and containment within, the heavily-
glycosylated synaptomatrix (Dani and Broadie, 2012; Martin, 2003), which is strongly 
compromised in mgat1 mutants. A range of known bi-directional signals regulate both NMJ 
structural development and synaptic strength (Enneking et al., 2013; Muller and Davis, 2012). 
The Broadie Lab has focused on three specific trans-synaptic cascades, mediated by the Wg, 
Gbb and Jeb signaling ligands (Grosso et al., 2011; Kamimura et al., 2013; Rohrbough and 
Broadie, 2010; Tanaka et al., 2002), and all three pathways were disrupted by the absence of 
mgat1 function (Chapter 2). The difficulty with current imaging of these trans-synaptic signals is 
that static pictures are taken, and thus signaling kinetics are completely unknown. An increase 
in the signal could occur from increased release, inappropriate sequestration, or lack of ligand 
uptake, among other possibilities. Parallel studies showed that trans-synaptic signaling 
regulates NMJ structure and function via recruitment of synaptic scaffolds which, in turn, 
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recruit pre- and postsynaptic molecular components (Ataman et al., 2006; Dani et al., 2012; 
Enneking et al., 2013; Koles et al., 2012; Muller and Davis, 2012). Consistently, two synaptic 
scaffolds, DLG and LGL, were reduced in mgat1 null mutants (Chapter 2), which normally 
regulate the distribution and density of both pre- and postsynaptic elements (Chen and 
Featherstone, 2005; Staples and Broadie, 2013). Importantly, dlg mutants exhibit impaired NMJ 
development, including deformed subsynaptic reticulum (SSR; Lahey et al., 1994), and 
preliminary ultrastructural analyses of mgat1 mutants reveals similar defects (Fig. 20). SSR 
phenotypes may be attributed to disrupted DLG and LGL scaffolds, but also may include other 
glycan contributions. The elevated synaptic vesicle number likely contributes to the increased 
neurotransmission and activity-dependent FM1-43 dye unloading in mgat1 mutants (Chapter 
2). Together, these results show Mgat1-dependent N-glycosylation regulates trans-synaptic 
signaling and thereby downstream synaptic localization of intracellular scaffolds driving 
neuromuscular synaptogenesis. 
 
Mgat1 Future Directions  
Immediate future studies on the role of hybrid and complex N-glycans in neuromuscular 
synaptogenesis will likely progress along two avenues. The first goal will be to comprehensively 
catalog the glycan changes occurring at the mgat1 null NMJ. The work done here only scratches 
the surface of available probes (Varki et al., 2009), and the extent of the synaptomatrix glycan 
changes remains largely unknown. A key hypothesis arising from this work is that Mgat1-
dependent glycosylation of known synaptic proteins puts the brakes on structural and 
functional NMJ development. Specifically, the hypothesis is that loss of HRP-epitope additions 
on known target proteins (Fasciclins, Neurotactin and Neuroglian; Paschinger et al., 2009) as 
well as VVA glycan additions on other targets (e.g. Dystoglycan; Haines et al., 2007) contribute 
to the mgat1 null phenotypes of over-elaborated synaptic architecture and increased 
neurotransmission strength, respectively (Chapter 2). To test this hypothesis, the glycosylation 
state of candidate proteins can be queried in mgat1 nulls compared to transgenic rescue 
conditions. Rescue of mgat1 synaptic phenotypes could also be assayed with over-expression of 
these candidate targets, although it is unknown whether this would overcome the glycosylation  
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Figure 20: Ultrastructural analysis reveals SSR development and SV concentration phenotypes 
SSR distribution and SV concentrations are altered in the mgat11 null mutant. (A) 
Representative images of wandering third instar 6/7 boutons and T-bars in genetic control 
(w1118) and mgat11/Df(2)BSC430. (B) Quantification of SSR/bouton area, Minor Axis 
length/bouton area, SSR membrane density as number of membranes/um, the distance of SSR 
separating the bouton and muscle along the minor axis, total SV number/bouton area and 
number of SV within 250 nm of clearly defined T-bars. Results show a trend for decreased ratio 
of SSR/Bouton area in the mutant, significant decrease in the minor axis length/bouton area 
and specifically the SSR separating the bouton from muscle but no change in the SSR 
membrane density measured by the number of plasma membranes per um. There is a strong 
increase in total number of SVs/bouton and SVs within 250nm of t-bars in the mutant.  
Statistical analysis using T-test shown as p≤0.01 (**) and p≤0.001 (***) compared to w1118.  
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requirements. Second, the role of trans-synaptic signaling defects in mgat1 null synaptogenic 
phenotypes needs to be more rigorously tested, and the mechanism directly addressed. 
Specifically, it is well-known that changes in signaling ligand abundance in the extracellular 
space can result in numerous possible outcomes for the actual relay of trans-synaptic signals 
(Dear et al., 2016). Changes in ligand abundance can be caused by changes in release, 
sequestration, degradation or presentation to cognate receptors, as put forth in the ‘exchange 
factor’ model of signaling (Yan et al., 2009). Thus, for each of the target pathways (Wg, Gbb, 
Jeb) downstream signaling needs to be tested via the Fz2-C nuclear import pathway, p-MAD 
and pERK signaling, respectively (Dani et al., 2012). Once the direction and degree of each 
signaling defect is defined, pathways can be individually or combinatorially corrected to test 
their impact on mgat1 null synaptic outcomes, as the Broadie Lab has done previously in other 
mutant contexts (Dani et al., 2012). Together, this future work will define the molecular 
mechanisms underlying Mgat1-dependent neuromuscular synaptogenesis. 
A severe short-coming of this Mgat1 work was the inability to identify and test specific 
glycan modifications on synaptic proteins. At the time of these studies this type of analysis was 
daunting; however, the technology is quickly becoming available to perform systematic assays 
(Koles et al., 2007; Kurz et al., 2015; Nilsson, 2016). Using older and newer techniques together, 
proteins can be 1) immuno-precipitated with lectins for specific glycan patterns, 2) cleave all 
glycan branches leaving a modified asparagine to then 3) identify all sites of previous glycans. A 
major direction will be the identification of specific branching patterns on candidate proteins to 
allow a directed approach for dissecting glycosylation roles. Although a monumental endeavor, 
producing mutants lacking glycosylation sites would be ideal for dissecting mgat1 mutant 
phenotypes. This work should reveal the role for specific glycan modifications in synaptic 
mechanisms. However, it may still be difficult to discern the temporal roles that glycosylation 
plays. For instance, an “early” glycan that is initially attached to a protein may be required for 
protein folding, and a “mature” glycan may be required for complex formation with other 
proteins at the final destination (Varki et al., 2009). Loss of either “early” or “mature” forms of 
the same glycan could result in the same outcome (i.e. loss of the protein at its intended 
target). One path forward could be to replicate studies on additional glycosylation enzymes that 
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are required for the addition or removal of hybrid and complex glycans (Baas et al., 2011; 
Leonard et al., 2006). In this manner, a smaller subset of glycosylation events could be studied, 
possibly reducing the number of total modifications. For instance, instead of using an mgat1 
mutant to block all hybrid and complex glycan formation, a future focus could be on the fucose 
transferase responsible for HRP epitope production (Rendic et al., 2006). In this manner, a 
dozen proteins might be affected instead of hundreds. The overall goal for this future work will 
be to identify the mechanisms by which specific glycan attachments mediate synaptic growth, 
structural integrity and functional communication properties.  
 
PMM2 Conclusions  
This study set forth to establish a new Drosophila PMM2-CDG disease model through 
mutation of the causative phosphomannomutase type 2 (pmm2) gene (Freeze et al., 2014). This 
was the first work to investigate Drosophila pmm2, so the study began by producing genetic 
nulls using CRISPR and characterizing transgenic RNAi lines. N-glycosylation is required for 
viability in all metazoa, plants and yeast cells (Varki et al., 2009), predicting very early lethality 
in Drosophila pmm2 null animals, with cellular viability only temporarily sustained by maternal 
contribution. As expected, loss of pmm2 reduced lifespan corresponding to PMM2 level; null 
mutants survive only briefly and are developmentally delayed as first instars almost 
immediately after hatching (Chapter 3). The presence of maternally contributed pmm2 mRNA 
was verified with quantitative reverse transcription PCR. Abundant transcripts were present in 
unfertilized eggs, explaining the embryonic survival of the null mutants. Mutant larva displayed 
reduced locomotion and adults with neurally-reduced pmm2 displayed severely impaired 
coordinated movement, with an inability to fly or even walk (Chapter 3). The adult movement 
loss was so severe that a new assay was needed for quantitative comparison (“ring locomotion” 
assay). There was a specific requirement for PMM2 within the nervous system, demonstrating 
that function in neurons is required to maintain coordinated movement and thus viability 
(Chapter 3). 
Null pmm2 mutants display severe reduction of glycoprotein glycosylation, with reduced 
N-linked glycosylation levels and diversity (Chapter 3). Consistently, the NMJ also showed 
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striking losses in synaptomatrix glycan composition with strong reduction of the HRP 
(bifucosylated N-glycan) and ECL (D-galactose) epitopes. Consistent with other glycosylation 
mutants (Dani et al., 2012, 2014; Jumbo-Lucioni et al., 2014; Parkinson et al., 2013), PMM2 loss 
caused striking NMJ overelaboration as well as strongly increased neurotransmission, 
supporting the conclusion that glycans primarily inhibit synaptic differentiation (Chapter 3). 
Loss of pmm2 on either side of the synapse resulted in overabundant NMJ structure.  
Interestingly, the elevated neurotransmission was only present with dual pre and postsynaptic 
pmm2 knockdown; wild type expression of pmm2 on either side of the synapse maintained 
control neurotransmission levels. This is an unusual result as mutations that alter 
neurotransmission strength typically have a primarly pre or postsynaptic requirement where 
loss on one side causes the primary phenotype; however, the pmm2 mutant phenotype 
requires dual loss on both sides of the synapse (Jumbo-Lucioni et al., 2014; Parkinson et al., 
2013; Staples and Broadie, 2013). Aditionally, this provides an example of the separable nature 
of NMJ structure with function where increased structure seen with pre or post knockdown did 
not correlate to elevated neurotransmission strength.  
During this study, it was revealed that pmm2 mutants show striking tracheal defects, 
with consistently fragmented and melanized trachea in larvae (Fig. 21). This striking phenotype 
caused trachea to appear like dark, broken sticks, which gave a strikingly distinct appearance to 
mutant larvae when moving and crawling. Importantly, this phenotype has been associated 
with mutation of extracellular matrix metalloproteinases (MMPs), which also play critical roles 
shaping synapse structure and function (Dear et al., 2016; Kessenbrock et al., 2010; Page-
McCaw et al., 2007; Sternlicht and Werb, 2001). Based on these observations, it was 
hypothesized that PMM2 loss could impair MMP glycosylation, or MMP ability to cleave 
improperly glycosylated substrates (Godenschwege et al., 2000; Llano et al., 2000; Llano et al., 
2002; Pohar et al., 1999). To test this hypothesis, we assayed the two MMPs present in 
Drosophila (secreted MMP1 and GPI-anchored MMP2), as well as the single Tissue Inhibitor of 
MMPs (TIMP) (Dear et al., 2016; Kessenbrock et al., 2010; Page-McCaw et al., 2007). MMP2 was 
found to be highly glycosylated, whereas most MMP1 isoforms were not detectably 
glycosylated (Chapter 3). Importantly, loss of PMM2-dependent MMP2 glycosylation resulted in  
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Figure 21: Tracheal Maintenance Requires pmm2 Activity 
Trachea break, melanize and harden with the reduction of pmm2.  Several breaks begin to form 
in the 2nd instar larva and in the 3rd instar trachea surrounding the breaks have begun to 
melanize and harden, giving the appearance of dark sticks underneath the cuticle. Arrows point 
at melanized trachea and breaks are shown with an “*”.    
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reduced expression at the NMJ synapse, whereas MMP1 abundance was not significantly 
altered. The TIMP regulator is also reduced in abundance with removal of PMM2, which would 
be predicted to either help alleviate consequences of MMP2 loss or amplify the dysregulated 
MMP1/MMP2 ratio that is required to maintain synaptic development and function (Dear et al., 
2016). We are unable to determine if the loss of TIMP is actively directed by the cell to limit its 
inhibition on the reduced levels of MMP2, or if the loss of TIMP is causative of the pmm2 
reduction and only serves to amplify the unregulated MMP1/MMP2 ratio, but both possibilities 
are interesting to consider.  
Recent work has shown that MMPs play critical roles regulating Drosophila NMJ 
structural and functional synaptogenesis via modulation of Wg trans-synaptic signaling (Dear et 
al., 2016). Consistently, pmm2 RNAi knockdown suppresses Wg signaling at the developing NMJ 
synapse (Chapter 3). Importantly, MMPs were recently shown to cleave the HSPG Wg co- 
receptor Dally-like Protein (Dlp) to control Wg signaling in the Drosophila ovary (Wang and 
Page-McCaw, 2014). Consistently, pmm2 RNAi knockdown strongly reduced synaptic levels of 
the Dlp Wg co-receptor as well as the Wg ligand (Chapter 3), and also strongly reduced 
downstream signaling through the Frizzled Nuclear Import (FNI) pathway (Speese et al., 2012). 
Impaired Wg signaling is a counter-intuitive result given the overelaborated structure and 
elevated function at the pmm2 mutant NMJ (Chapter 3) because Wg loss has previously been 
associated with decreased NMJ structure and functional development (Ataman et al., 2008; 
Kerr et al., 2014; Packard et al., 2002). The reduced Wg signaling could be a result of several 
possibilities including MMP2 interactions, Wg and Fz2 receptor glycosylation requirements and 
Wg reduction to compensate for increased synaptic development. The last possibility is the 
most tempting, since it would best account for the decrease in Wg signaling that typically drives 
NMJ outgrowth and increased function (Ataman et al., 2008; Kerr et al., 2014; Packard et al., 
2002). However, there is as yet no evidence to support this hypothesis. PMM2-dependent 
glycosylation at the NMJ synapse may reflect roles in multiple intersecting pathways, impacting 
a range of glycoproteins that jointly control synaptic growth, structural differentiation and 
neurotransmission strength (Koles et al., 2007; Scott and Panin, 2014). Future work will aim at 
deciphering individual glycan contributions, which are presumed to combinatorially result in 
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the structural and functional NMJ defects characterizing this new PMM2-CDG disease state 
model. 
 
PMM2 Future Directions  
Numerous research directions could be pursued to improve the Drosophila PMM2-CDG 
disease model. The first important avenue would be to produce rescue constructs to verify the 
specificity of pmm2 mutant phenotypes. Although rescue constructs were made for this thesis, 
they were ineffectual in preventing the early lethality. The primary suspected reason is that an 
incorporated His tag in the rescue constructs prevented function, or even resulted in a 
dominant lethal form of pmm2. Future work should aim at redesigning the rescue construct, 
either without any tags or with the use of more conventional tags at different locations (Koles 
et al., 2015; Richier and Salecker, 2015). A second important avenue would be to generate 
human pmm2 rescue constructs in order to test functional conservation, always a key priority in 
establishing a disease model. If human pmm2 is able to rescue the Drosophila null mutant, then 
constructs with the most common human disease causing mutations should also be generated 
(Barone et al., 2014; Pagon et al., 2014). The most common human pmm2 mutation is R141H  
with L32R being the second most common. The R141H mutation is homozygous lethal with less 
than 3% enzymatic activity but the heterozygous condition is asymptomatic. The vast majority 
of PMM2-CDG patients have compound heterozygous mutations which results in a wide array 
of symptoms that include mental retardation, psychomotor disability and failure to thrive 
(Barone et al., 2014 a,b). These human PMM2-CDG lines would provide an excellent platform to 
study hypomorphic pmm2 activity in a simplified system.  
Another future direction stems from work in the zebrafish PMM2-CDG disease model, 
which suggests a role for increased mannose-6-phosphate in PMM2-CDG disease state 
phenotypes (Cline et al., 2012). Further work is needed to dissect the possible roles played by 
altered abundance of glycan precursors, particularly mannose-6-phosphate buildup, through 
examining genetic interactions that restore the relative abundance of these pools. Utilizing the 
Drosophila genetic toolkit, it would be relatively easy to knockdown PMM2 and 
phosphomannoisomerase (MPI or PMI) simultaneously (Sharma et al., 2014), thus reducing the 
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elevated levels of mannose-6-phosphate in pmm2 mutants. This line of study would first involve 
tests of MPI mutant phenotypes, and then the effects of combined MPI and pmm2 mutations in 
both behavioral and synaptic structure/function assays (Chapter 3). In parallel, simple over-
expression MPI in a control background could be very informative for correlative comparisons 
of phenotypes, to decipher possible phenotypes caused by the loss of glycosylation verses 
mannose-6-phosphate accumulation (Cline et al., 2012; Sharma et al., 2014). Dependent on 
outcomes, potential treatments could be targeted approaches to reduce MPI activity with 
pharmacology. MPI can be inhibited with pharmaceutical inhibitors in the benzoisothiazolone 
series, which have been shown to promote mannose-1-phosphate production in PMM2-CDG 
patient fibroblasts and zebrafish embryos (Sharma et al., 2011). Although this possible future 
research avenue has a relatively strong foundation, even if reducing MPI activity in humans 
alleviated the symptoms from increased mannose-6-phosphate, the patients still have a 
reduction in glycosylation that will not be alleviated.  
A primary aspiration for any disease model is to find effective treatments for a 
conserved disease state, and a goal for this new Drosophila MPP2-CDG model is to explore a 
range of pharmaceutical options. For example, drug avenues to increase PMM2 enzymatic 
activity have been hypothesized, but have not yet been systematically tested (Thiel and Korner, 
2013). There are over 100 known different pmm2 mutations that cause the PMM2-CDG disease 
state, and each mutation affects the enzymatic activity in a different manner (Freeze et al., 
2014). This may significantly hamper the ability for any one drug intervention to aid all PMM2-
CDG cases. However, future studies could focus particularly on drugs that act as chaperones 
that help PMM2 form the functional homodimer complex, as multiple mutations result 
specifically in the loss of dimer formation (Yuste-Checa et al., 2014). Another potential path 
forward would be to focus on other enzymes in the pathway with closely related functions. For 
example, PMM2 has a sibling enzyme phosphomannomutase type 1 (PMM1), which functions 
as a glucose-1,6-biphosphatase and is expressed strongly in the nervous system (Veiga-da-
Cunha et al., 2008). PMM1 and PMM2 share structural and functional similarity, but have 
different in vivo substrates such that PMM1 does not compensate for PMM2 loss (Veiga-da-
Cunha et al., 2008). Interestingly, however, PMM1 activity in vitro does convert mannose-6-
152 
 
phosphate into mannose-1-phosphate, revealing the ability for PMM1 to perform the PMM2 
enzymatic role (Pirard et al., 1999). A research avenue could focus on finding pharmaceutical 
reagents that drive PMM1 to function more like PMM2. Even weakly driving PMM1 towards 
PMM2 activity could greatly improve patient development, given the hypomorphic nature of 
the disease state and especially since PMM1 is strongly expressed in neural tissue. A large-
scale, small molecule pharmaceutical screen using the new Drosophila PMM2-CDG model could 
prove very effective (Giacomotto and Segalat, 2010). Our hope and expectation is that future 
studies utilizing the powerful Drosophila genetic toolkit will further our understanding of the 
PMM2-CDG disease state and provide the means to produce as effective therapy.   
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